Glucocorticoid	O
receptor	O
activation	O
and	O
inactivation	O
in	O
c	O
ultured	B-cell_line
human	I-cell_line
lymphocytes	I-cell_line
.	O

Although	O
glucocorticoids	O
are	O
not	O
cytolytic	O
for	O
and	O
do	O
not	O
inhibit	O
the	O
growth	O
of	O
the	O
IM-9	B-cell_line
line	I-cell_line
of	O
cultured	B-cell_line
human	I-cell_line
lymphoblasts	I-cell_line
,	O
these	O
cells	O
have	O
a	O
high	O
steroid-binding	O
capacity	O
.	O

We	O
have	O
used	O
IM-9	B-cell_type
cells	I-cell_type
in	O
order	O
to	O
examine	O
whether	O
unoccupied	B-protein
glucocorticoid	I-protein
receptors	I-protein
are	O
inactivated	O
and	O
activated	O
in	O
intact	B-cell_type
cells	I-cell_type
.	O

when	O
IM-9	B-cell_type
cells	I-cell_type
are	O
incubated	O
in	O
glucose-free	O
medium	O
in	O
a	O
nitrogen	O
atmosphere	O
,	O
both	O
their	O
ability	O
to	O
bind	O
triamcinolone	O
acetonide	O
and	O
their	O
ATP	O
levels	O
decline	O
and	O
,	O
when	O
glucose	O
and	O
oxygen	O
are	O
reintroduced	O
,	O
ATP	O
levels	O
and	O
receptor	O
activity	O
return	O
.	O

The	O
specific	O
glucocorticoid-binding	O
activity	O
of	O
cytosol	O
prepared	O
from	O
cells	O
exposed	O
to	O
various	O
degrees	O
of	O
energy	O
limitation	O
is	O
directly	O
correlated	O
with	O
the	O
ATP	O
content	O
.	O

Receptor	O
activation	O
in	O
intact	B-cell_type
cells	I-cell_type
is	O
rapid	O
and	O
independent	O
of	O
protein	O
synthesis	O
.	O

Cytosol	O
prepared	O
from	O
inactivated	O
cells	O
can	O
not	O
be	O
activated	O
by	O
addition	O
of	O
ATP	O
.	O

The	O
inactivation	O
of	O
glucocorticoid	B-protein
receptors	I-protein
that	O
occurs	O
when	O
cytosol	O
from	O
normal	O
IM-9	B-cell_line
cells	I-cell_line
is	O
incubated	O
at	O
25	O
degrees	O
C	O
is	O
inhibited	O
by	O
molybdate	O
,	O
vanadate	O
,	O
fluoride	O
,	O
ATP	O
,	O
and	O
several	O
other	O
nucleotides	O
.	O

The	O
experiments	O
with	O
intact	B-cell_type
human	I-cell_type
lymphoblasts	I-cell_type
suggest	O
that	O
assays	O
of	O
specific	O
glucocorticoid-binding	O
capacity	O
do	O
not	O
necessarily	O
reflect	O
the	O
cellular	O
content	O
of	O
receptor	B-protein
protein	I-protein
.	O

31111	NULL
:	NULL
gugN/AL	NULL
fr	NULL
Brotrocicat	NULL
Cremistry	NULL
ol	NULL
.	NULL

,	NULL
No	NULL
.	NULL

1	NULL
,	NULL
Issue	NULL
of	NULL
Janu	NULL
10	NULL
,	NULL
pp	NULL
.	NULL

434-441	NULL
,	NULL
1981	NULL
Printed	NULL
in	NULL
U.S.	NULL
A.	NULL
ary	NULL
10.	NULL
pp	NULL
98	NULL
Glucocorticoid	NULL
Receptor	NULL
Activation	NULL
and	NULL
Inactivation	NULL
in	NULL
Cultured	NULL
Human	NULL
Lymphocytes*	NULL
(	NULL
Received	NULL
for	NULL
publication	NULL
,	NULL
February	NULL
27	NULL
,	NULL
1980	NULL
,	NULL
and	NULL
in	NULL
revised	NULL
form	NULL
,	NULL
September	NULL
15	NULL
,	NULL
1980	NULL
)	NULL
Richard	NULL
H.	NULL
Wheeler	NULL
}	NULL
,	NULL
Karen	NULL
L.	NULL
Leach§	NULL
,	NULL
Ann	NULL
C.	NULL
La	NULL
Forest§	NULL
,	NULL
Timothy	NULL
E	NULL
.	NULL

O'Toole	NULL
?	NULL
}	NULL

,	NULL
Renate	NULL
Wagnert	NULL
,	NULL
and	NULL
William	NULL
B.	NULL
Pratt§	NULL
From	NULL
the	NULL
Departments	NULL
of	NULL
{	NULL
Internal	NULL
Medicine	NULL
and	NULL
§Pharmacology	NULL
,	NULL
The	NULL
University	NULL
of	NULL
Michigan	NULL
School	NULL
of	NULL
Medicine	NULL
,	NULL
Ann	NULL
Arbor	NULL
,	NULL
Michigan	NULL
48109	NULL
Although	NULL
glucocorticoids	NULL
are	NULL
not	NULL
cytolytic	NULL
for	NULL
and	NULL
do	NULL
not	NULL
inhibit	NULL
the	NULL
growth	NULL
of	NULL
the	NULL
IM-9	NULL
line	NULL
of	NULL
cultured	NULL
human	NULL
lymphoblasts	NULL
,	NULL
these	NULL
cells	NULL
have	NULL
a	NULL
high	NULL
steroid-binding	NULL
capacity	NULL
.	NULL

We	NULL
have	NULL
used	NULL
IM-9	NULL
cells	NULL
in	NULL
order	NULL
to	NULL
examine	NULL
whether	NULL
unoccupied	NULL
glucocorticoid	NULL
receptors	NULL
are	NULL
inactivated	NULL
and	NULL
activated	NULL
in	NULL
intact	NULL
cells	NULL
.	NULL

When	NULL
IM-9	NULL
cells	NULL
are	NULL
incubated	NULL
in	NULL
glucose-free	NULL
medium	NULL
in	NULL
a	NULL
nitrogen	NULL
atmosphere	NULL
,	NULL
both	NULL
their	NULL
ability	NULL
to	NULL
bind	NULL
triamcinolone	NULL
acetonide	NULL
and	NULL
their	NULL
ATP	NULL
levels	NULL
decline	NULL
and	NULL
,	NULL
when	NULL
glucose	NULL
and	NULL
oxgen	NULL
are	NULL
reintroduced	NULL
,	NULL
ATP	NULL
levels	NULL
and	NULL
receptor	NULL
activity	NULL
return	NULL
.	NULL

The	NULL
specific	NULL
glucocorticoid-binding	NULL
activity	NULL
of	NULL
cytosol	NULL
prepared	NULL
from	NULL
cells	NULL
exposed	NULL
to	NULL
various	NULL
degrees	NULL
of	NULL
energy	NULL
limitation	NULL
is	NULL
directly	NULL
correlated	NULL
with	NULL
the	NULL
ATP	NULL
content	NULL
.	NULL

Receptor	NULL
activation	NULL
in	NULL
intact	NULL
cells	NULL
is	NULL
rapid	NULL
and	NULL
independent	NULL
of	NULL
protein	NULL
synthe-sis	NULL
.	NULL

Cytosol	NULL
prepared	NULL
from	NULL
inactivated	NULL
cells	NULL
can	NULL
not	NULL
be	NULL
activated	NULL
by	NULL
addition	NULL
of	NULL
ATP	NULL
.	NULL

The	NULL
inactivation	NULL
of	NULL
glucocorticoid	NULL
receptors	NULL
that	NULL
occurs	NULL
when	NULL
cytosol	NULL
from	NULL
normal	NULL
IM-9	NULL
cells	NULL
is	NULL
incubated	NULL
at	NULL
25°C	NULL
is	NULL
inhibited	NULL
by	NULL
molybdate	NULL
,	NULL
vanadate	NULL
,	NULL
fluoride	NULL
,	NULL
ATP	NULL
,	NULL
and	NULL
several	NULL
other	NULL
nucleotides	NULL
.	NULL

The	NULL
experiments	NULL
with	NULL
intact	NULL
human	NULL
lymphoblasts	NULL
suggest	NULL
that	NULL
assays	NULL
of	NULL
specific	NULL
glucocorticoid-binding	NULL
capacity	NULL
do	NULL
not	NULL
necessarily	NULL
reflect	NULL
the	NULL
cellular	NULL
content	NULL
of	NULL
receptor	NULL
protein	NULL
.	NULL

Several	NULL
years	NULL
ago	NULL
,	NULL
Munck	NULL
and	NULL
Brinck-Johnsen	NULL
(	NULL
1	NULL
)	NULL
demonstrated	NULL
that	NULL
the	NULL
specific	NULL
binding	NULL
observed	NULL
in	NULL
intact	NULL
rat	NULL
thymic	NULL
lymphocytes	NULL
incubated	NULL
with	NULL
radiolabeled	NULL
cortisol	NULL
can	NULL
be	NULL
reduced	NULL
by	NULL
exposing	NULL
the	NULL
cells	NULL
to	NULL
nitrogen	NULL
and	NULL
restored	NULL
by	NULL
returning	NULL
them	NULL
to	NULL
an	NULL
oxygen	NULL
atmosphere	NULL
.	NULL

The	NULL
alterations	NULL
in	NULL
specific	NULL
binding	NULL
were	NULL
accompanied	NULL
by	NULL
similar	NULL
changes	NULL
in	NULL
ATP	NULL
.	NULL

Munck	NULL
et	NULL
al	NULL
.	NULL

(	NULL
2	NULL
)	NULL
subsequently	NULL
proposed	NULL
that	NULL
ATP	NULL
might	NULL
be	NULL
required	NULL
to	NULL
maintain	NULL
glucocorticoid	NULL
receptors	NULL
in	NULL
a	NULL
steroid-binding	NULL
form	NULL
(	NULL
2	NULL
)	NULL
.	NULL

Other	NULL
more	NULL
indirect	NULL
observations	NULL
made	NULL
in	NULL
intact	NULL
cells	NULL
exposed	NULL
to	NULL
metabolic	NULL
inhibitors	NULL
support	NULL
this	NULL
hypothesis	NULL
(	NULL
3-6	NULL
)	NULL
.	NULL

We	NULL
have	NULL
recently	NULL
presented	NULL
several	NULL
types	NULL
of	NULL
evidence	NULL
in	NULL
support	NULL
of	NULL
the	NULL
proposal	NULL
that	NULL
unoccupied	NULL
glucocorticoid	NULL
receptors	NULL
under	NULL
cell-free	NULL
conditions	NULL
are	NULL
inactivated	NULL
by	NULL
a	NULL
dephos-phorylation	NULL
process	NULL
(	NULL
7-9	NULL
)	NULL
.	NULL

We	NULL
have	NULL
shown	NULL
that	NULL
inactivated	NULL
receptors	NULL
in	NULL
cytosols	NULL
prepared	NULL
from	NULL
mouse	NULL
L-cells	NULL
or	NULL
rat	NULL
thymic	NULL
lymphocytes	NULL
can	NULL
be	NULL
reactivated	NULL
to	NULL
the	NULL
steroid-binding	NULL
*	NULL
This	NULL
investigation	NULL
was	NULL
supported	NULL
by	NULL
a	NULL
grant	NULL
from	NULL
the	NULL
Children	NULL
's	NULL
Leukemia	NULL
Foundation	NULL
of	NULL
Michigan	NULL
and	NULL
by	NULL
Grant	NULL
CA-16041	NULL
awarded	NULL
by	NULL
the	NULL
National	NULL
Cancer	NULL
Institute	NULL
.	NULL

The	NULL
project	NULL
was	NULL
initiated	NULL
with	NULL
funds	NULL
provided	NULL
by	NULL
Institutional	NULL
Research	NULL
Cancer	NULL
Grant	NULL
IN-40R	NULL
to	NULL
the	NULL
University	NULL
of	NULL
Michigan	NULL
from	NULL
the	NULL
American	NULL
Cancer	NULL
Society	NULL
.	NULL

The	NULL
costs	NULL
of	NULL
publication	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
the	NULL
payment	NULL
of	NULL
page	NULL
charges	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
adver-tisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

Section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

form	NULL
by	NULL
a	NULL
process	NULL
that	NULL
utilizes	NULL
ATP	NULL
and	NULL
a	NULL
heat	NULL
stable	NULL
factor	NULL
(	NULL
10-12	NULL
)	NULL
.	NULL

Activation	NULL
of	NULL
the	NULL
receptor	NULL
by	NULL
phosphorylation	NULL
has	NULL
not	NULL
yet	NULL
been	NULL
directly	NULL
demonstrated	NULL
,	NULL
and	NULL
it	NULL
is	NULL
not	NULL
known	NULL
if	NULL
the	NULL
phosphorylated	NULL
moiety	NULL
is	NULL
the	NULL
steroid-binding	NULL
protein	NULL
itself	NULL
or	NULL
if	NULL
some	NULL
other	NULL
component	NULL
required	NULL
for	NULL
steroid-binding	NULL
activity	NULL
is	NULL
activated	NULL
and	NULL
inactivated	NULL
by	NULL
a	NULL
phosphorylation-dephos-phorylation	NULL
mechanism	NULL
.	NULL

It	NULL
is	NULL
important	NULL
to	NULL
note	NULL
that	NULL
we	NULL
are	NULL
using	NULL
the	NULL
term	NULL
``	NULL
activation	NULL
``	NULL
throughout	NULL
this	NULL
paper	NULL
to	NULL
describe	NULL
the	NULL
process	NULL
whereby	NULL
the	NULL
receptor	NULL
is	NULL
converted	NULL
from	NULL
a	NULL
nonbinding	NULL
form	NULL
to	NULL
a	NULL
form	NULL
that	NULL
binds	NULL
steroids	NULL
.	NULL

This	NULL
is	NULL
different	NULL
from	NULL
the	NULL
use	NULL
of	NULL
the	NULL
term	NULL
``	NULL
activation	NULL
``	NULL
to	NULL
describe	NULL
the	NULL
process	NULL
whereby	NULL
the	NULL
steroid-bound	NULL
receptor	NULL
is	NULL
converted	NULL
to	NULL
a	NULL
form	NULL
that	NULL
binds	NULL
to	NULL
nuclei	NULL
,	NULL
DNA	NULL
cellulose	NULL
,	NULL
etc	NULL
.	NULL

We	NULL
use	NULL
the	NULL
term	NULL
``	NULL
transformation	NULL
``	NULL
to	NULL
describe	NULL
this	NULL
latter	NULL
process	NULL
.	NULL

The	NULL
possibility	NULL
exists	NULL
that	NULL
receptors	NULL
may	NULL
be	NULL
able	NULL
to	NULL
be	NULL
switched	NULL
on	NULL
and	NULL
off	NULL
in	NULL
a	NULL
rapid	NULL
and	NULL
reversible	NULL
manner	NULL
.	NULL

Such	NULL
a	NULL
process	NULL
could	NULL
be	NULL
an	NULL
important	NULL
mechanism	NULL
for	NULL
regulating	NULL
the	NULL
ability	NULL
of	NULL
the	NULL
cell	NULL
to	NULL
respond	NULL
to	NULL
steroids	NULL
.	NULL

If	NULL
the	NULL
concept	NULL
is	NULL
correct	NULL
,	NULL
one	NULL
should	NULL
be	NULL
able	NULL
to	NULL
demonstrate	NULL
that	NULL
receptors	NULL
can	NULL
be	NULL
inactivated	NULL
and	NULL
reactivated	NULL
in	NULL
the	NULL
intact	NULL
cell	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
hormone	NULL
.	NULL

Bell	NULL
and	NULL
Munck	NULL
(	NULL
13	NULL
)	NULL
have	NULL
published	NULL
an	NULL
experiment	NULL
performed	NULL
with	NULL
rat	NULL
thymic	NULL
lymphocytes	NULL
suggesting	NULL
this	NULL
is	NULL
possible	NULL
.	NULL

In	NULL
other	NULL
experiments	NULL
,	NULL
intact	NULL
cells	NULL
were	NULL
incubated	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
radiolabeled	NULL
steroid	NULL
(	NULL
1-4	NULL
,	NULL
6	NULL
)	NULL
and	NULL
the	NULL
results	NULL
are	NULL
subject	NULL
to	NULL
a	NULL
variety	NULL
of	NULL
interpretations	NULL
as	NULL
the	NULL
steroid	NULL
:	NULL
receptor	NULL
complex	NULL
is	NULL
able	NULL
to	NULL
cycle	NULL
into	NULL
and	NULL
out	NULL
of	NULL
the	NULL
nucleus	NULL
.	NULL

The	NULL
purpose	NULL
of	NULL
this	NULL
paper	NULL
is	NULL
to	NULL
demonstrate	NULL
that	NULL
unoccupied	NULL
glucocorticoid	NULL
receptors	NULL
can	NULL
be	NULL
readily	NULL
inactivated	NULL
and	NULL
activated	NULL
in	NULL
intact	NULL
cells	NULL
.	NULL

Activation	NULL
is	NULL
rapid	NULL
,	NULL
independent	NULL
of	NULL
protein	NULL
synthesis	NULL
,	NULL
and	NULL
directly	NULL
correlated	NULL
to	NULL
cellular	NULL
ATP	NULL
content	NULL
.	NULL

As	NULL
variation	NULL
in	NULL
receptor	NULL
activity	NULL
could	NULL
explain	NULL
differences	NULL
in	NULL
responses	NULL
observed	NULL
clinically	NULL
with	NULL
steroid	NULL
therapy	NULL
,	NULL
we	NULL
have	NULL
chosen	NULL
cultured	NULL
lymphoblasts	NULL
of	NULL
human	NULL
origin	NULL
for	NULL
the	NULL
experimental	NULL
system	NULL
.	NULL

EXPERIMENTAL	NULL
PROCEDURES	NULL
Materials	NULL
{	NULL
1,2,3-°H	NULL
)	NULL
Triamcinolone	NULL
acetonide	NULL
'	NULL
(	NULL
46	NULL
Ci/mmol	NULL
,	NULL
diluted	NULL
to	NULL
5.6	NULL
Ci/	NULL
mmol	NULL
prior	NULL
to	NULL
use	NULL
)	NULL
and	NULL
[	NULL
°H	NULL
]	NULL
leucine	NULL
(	NULL
56.5	NULL
Ci/mmol	NULL
)	NULL
were	NULL
obtained	NULL
from	NULL
New	NULL
England	NULL
Nuclear	NULL
.	NULL

Nonradioactive	NULL
dexamethasone	NULL
,	NULL
ATP	NULL
(	NULL
disodium	NULL
salt	NULL
from	NULL
equine	NULL
muscle	NULL
,	NULL
substantially	NULL
vanadium	NULL
free	NULL
)	NULL
,	NULL
ADP	NULL
,	NULL
AMP	NULL
,	NULL
GTP	NULL
,	NULL
CTP	NULL
,	NULL
UTP	NULL
,	NULL
and	NULL
dithiothreitol	NULL
were	NULL
from	NULL
Sigma	NULL
.	NULL

Sodium	NULL
metavanadate	NULL
was	NULL
obtained	NULL
from	NULL
Matheson	NULL
,	NULL
Coleman	NULL
and	NULL
Bell	NULL
,	NULL
Norwood	NULL
,	NULL
Ohio	NULL
,	NULL
and	NULL
was	NULL
dissolved	NULL
by	NULL
boiling	NULL
in	NULL
the	NULL
appropriate	NULL
buffer	NULL
.	NULL

NADP	NULL
,	NULL
glucose-6-phosphate	NULL
dehydrogenase	NULL
(	NULL
EC	NULL
1.1.1.49	NULL
)	NULL
from	NULL
'The	NULL
abbreviations	NULL
and	NULL
trivial	NULL
names	NULL
used	NULL
are	NULL
:	NULL
triamcinolone	NULL
acetonide	NULL
,	NULL
_	NULL
3,20-dione	NULL
16,17-acetonide	NULL
;	NULL
dexamethasone	NULL
,	NULL
Qa-fluoro-l6a-methyl-118,17a,21-trihydroxypregna-1,4-diene-3,20-dione	NULL
;	NULL
Hepes	NULL
,	NULL
4-	NULL
(	NULL
2-hy-droxyethyl	NULL
)	NULL
-1-piperazineethanesulfonic	NULL
acid	NULL
.	NULL

434	NULL
Glucocorticoid	NULL
Receptor	NULL
Activation	NULL
and	NULL
Inactivation	NULL
yeast	NULL
,	NULL
and	NULL
hexokinase	NULL
(	NULL
EC	NULL
2.7.1.1	NULL
)	NULL
from	NULL
yeast	NULL
were	NULL
from	NULL
Boehringer	NULL
Mannheim	NULL
Biochemicals	NULL
,	NULL
Indianapolis	NULL
.	NULL

Modified	NULL
minimal	NULL
essential	NULL
medium	NULL
,	NULL
RPMI	NULL
1640	NULL
,	NULL
and	NULL
the	NULL
same	NULL
medium	NULL
without	NULL
glucose	NULL
were	NULL
obtained	NULL
from	NULL
Grand	NULL
Island	NULL
Biological	NULL
Co.	NULL
,	NULL
Grand	NULL
Island	NULL
,	NULL
N.Y.	NULL
Fetal	NULL
calf	NULL
serum	NULL
(	NULL
not	NULL
heat	NULL
inactivated	NULL
)	NULL
was	NULL
from	NULL
Kansas	NULL
City	NULL
Biologicals	NULL
,	NULL
Kansas	NULL
City	NULL
,	NULL
Kansas	NULL
.	NULL

All	NULL
other	NULL
materials	NULL
were	NULL
reagent	NULL
grade	NULL
.	NULL

Methods	NULL
Cell	NULL
Lines	NULL
and	NULL
Culture-The	NULL
Raji	NULL
,	NULL
EB-3	NULL
,	NULL
and	NULL
Jijoye	NULL
lines	NULL
of	NULL
Burkitt	NULL
lymphoma	NULL
were	NULL
purchased	NULL
from	NULL
the	NULL
American	NULL
Type	NULL
Culture	NULL
Collection	NULL
and	NULL
the	NULL
P	NULL
;	NULL
J	NULL
line	NULL
was	NULL
provided	NULL
by	NULL
Dr.	NULL
Charles	NULL
Shipman	NULL
of	NULL
the	NULL
Department	NULL
of	NULL
Oral	NULL
Biology	NULL
at	NULL
the	NULL
University	NULL
of	NULL
Michigan	NULL
Dental	NULL
School	NULL
.	NULL

The	NULL
IM-9	NULL
cell	NULL
line	NULL
was	NULL
obtained	NULL
from	NULL
the	NULL
laboratory	NULL
of	NULL
Dr.	NULL
Jesse	NULL
Roth	NULL
at	NULL
the	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
.	NULL

The	NULL
Burkitt	NULL
and	NULL
the	NULL
IM-9	NULL
(	NULL
derived	NULL
from	NULL
a	NULL
patient	NULL
with	NULL
multiple	NULL
myeloma	NULL
)	NULL
are	NULL
established	NULL
human	NULL
lymphoblastoid	NULL
cell	NULL
lines	NULL
of	NULL
the	NULL
bone	NULL
marrow-derived	NULL
(	NULL
B-cell	NULL
)	NULL
type	NULL
(	NULL
14	NULL
)	NULL
.	NULL

The	NULL
P	NULL
;	NULL
J	NULL
and	NULL
IM-9	NULL
cell	NULL
lines	NULL
have	NULL
a	NULL
doubling	NULL
time	NULL
of	NULL
15	NULL
to	NULL
18	NULL
h	NULL
during	NULL
the	NULL
log	NULL
phase	NULL
of	NULL
growth	NULL
and	NULL
the	NULL
Raji	NULL
,	NULL
EB-3	NULL
,	NULL
and	NULL
Jjoye	NULL
lines	NULL
double	NULL
in	NULL
about	NULL
24	NULL
h.	NULL
The	NULL
IM-9	NULL
line	NULL
was	NULL
demonstrated	NULL
to	NULL
contain	NULL
appropriate	NULL
isoenzyme	NULL
markers	NULL
(	NULL
lactic	NULL
dehydrogenase	NULL
,	NULL
EC	NULL
1.1.1.27	NULL
;	NULL
malic	NULL
dehydrogenase	NULL
,	NULL
EC	NULL
1.1.1.37	NULL
;	NULL
glucose-6-phosphate	NULL
dehydrogenase	NULL
,	NULL
EC	NULL
1.1.1.49	NULL
;	NULL
triosephosphate	NULL
isomerase	NULL
,	NULL
EC	NULL
5.3.1.1	NULL
;	NULL
glyoxalase	NULL
I	NULL
,	NULL
EC	NULL
4.4.1.5	NULL
;	NULL
and	NULL
phosphoglucomutase	NULL
,	NULL
EC	NULL
2.7.5.1	NULL
)	NULL
of	NULL
human	NULL
origin	NULL
in	NULL
the	NULL
laboratory	NULL
of	NULL
Dr.	NULL
Harvey	NULL
Mohrenweiser	NULL
,	NULL
in	NULL
the	NULL
Department	NULL
of	NULL
Human	NULL
Genetics	NULL
at	NULL
the	NULL
University	NULL
of	NULL
Michigan	NULL
Medical	NULL
School	NULL
(	NULL
15	NULL
)	NULL
.	NULL

The	NULL
cell	NULL
lines	NULL
were	NULL
maintained	NULL
in	NULL
stationary	NULL
suspension	NULL
culture	NULL
at	NULL
37°C	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
containing	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
,	NULL
100	NULL
units/ml	NULL
of	NULL
sodium	NULL
penicillin	NULL
G	NULL
,	NULL
and	NULL
100	NULL
ug/ml	NULL
of	NULL
streptomycin	NULL
.	NULL

The	NULL
effect	NULL
of	NULL
glucocorticoid	NULL
on	NULL
cell	NULL
growth	NULL
and	NULL
viability	NULL
was	NULL
assayed	NULL
in	NULL
triplicate	NULL
10-ml	NULL
cultures	NULL
in	NULL
30-ml	NULL
plastic	NULL
Falcon	NULL
flasks	NULL
.	NULL

Cells	NULL
were	NULL
counted	NULL
with	NULL
a	NULL
Coulter	NULL
counter	NULL
and	NULL
viability	NULL
was	NULL
determined	NULL
by	NULL
erythrocin	NULL
B	NULL
dye	NULL
exclusion	NULL
(	NULL
16	NULL
)	NULL
.	NULL

For	NULL
experiments	NULL
involving	NULL
steroid-receptor	NULL
assays	NULL
,	NULL
100-	NULL
or	NULL
200-ml	NULL
cultures	NULL
were	NULL
grown	NULL
in	NULL
one-liter	NULL
Blake	NULL
bottles	NULL
(	NULL
Corning	NULL
Glass	NULL
Works	NULL
)	NULL
equilibrated	NULL
with	NULL
5	NULL
%	NULL
CO	NULL
;	NULL
in	NULL
air	NULL
and	NULL
harvested	NULL
by	NULL
low	NULL
speed	NULL
centrifugation	NULL
during	NULL
the	NULL
log	NULL
phase	NULL
of	NULL
growth	NULL
.	NULL

Cell	NULL
Fractionation	NULL
and	NULL
Steroid-binding	NULL
Assay-IM-9	NULL
cells	NULL
were	NULL
ruptured	NULL
by	NULL
suspension	NULL
in	NULL
1.5	NULL
volumes	NULL
of	NULL
hypotonic	NULL
buffer	NULL
(	NULL
10	NULL
mm	NULL
Tris	NULL
,	NULL
pH	NULL
7.35	NULL
,	NULL
and	NULL
0.1	NULL
mm	NULL
EDTA	NULL
)	NULL
and	NULL
Dounce	NULL
homogenization	NULL
.	NULL

Complete	NULL
cell	NULL
rupture	NULL
(	NULL
verified	NULL
by	NULL
microscopic	NULL
examination	NULL
)	NULL
is	NULL
achieved	NULL
with	NULL
this	NULL
procedure	NULL
.	NULL

In	NULL
those	NULL
experiments	NULL
where	NULL
receptor	NULL
inactivation	NULL
was	NULL
examined	NULL
in	NULL
cytosol	NULL
at	NULL
25°C	NULL
,	NULL
cells	NULL
were	NULL
ruptured	NULL
in	NULL
Tris	NULL
buffer	NULL
that	NULL
was	NULL
adjusted	NULL
to	NULL
pH	NULL
7.35	NULL
at	NULL
that	NULL
temperature	NULL
.	NULL

In	NULL
all	NULL
other	NULL
experiments	NULL
,	NULL
the	NULL
Tris	NULL
was	NULL
pH	NULL
adjusted	NULL
at	NULL
0°C	NULL
.	NULL

The	NULL
ruptured	NULL
cell	NULL
suspension	NULL
was	NULL
centrifuged	NULL
for	NULL
15	NULL
min	NULL
at	NULL
27,000	NULL
x	NULL
g	NULL
and	NULL
the	NULL
resulting	NULL
supernatant	NULL
was	NULL
recentrifuged	NULL
for	NULL
1	NULL
h	NULL
at	NULL
100,000	NULL
x	NULL
g.	NULL
Supernatants	NULL
,	NULL
100,000	NULL
x	NULL
g	NULL
,	NULL
were	NULL
also	NULL
prepared	NULL
from	NULL
rat	NULL
liver	NULL
homogenized	NULL
in	NULL
10	NULL
mm	NULL
Hepes	NULL
buffer	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
7	NULL
)	NULL
.	NULL

All	NULL
fractionation	NULL
procedures	NULL
were	NULL
carried	NULL
out	NULL
at	NULL
0-4°C	NULL
.	NULL

The	NULL
resulting	NULL
cytosol	NULL
preparation	NULL
was	NULL
quick	NULL
frozen	NULL
,	NULL
stored	NULL
at	NULL
-70°C	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
10	NULL
)	NULL
,	NULL
and	NULL
thawed	NULL
just	NULL
prior	NULL
to	NULL
use	NULL
by	NULL
warming	NULL
at	NULL
20°C	NULL
.	NULL

The	NULL
liquid	NULL
was	NULL
removed	NULL
and	NULL
transferred	NULL
to	NULL
an	NULL
ice	NULL
bath	NULL
as	NULL
thawing	NULL
took	NULL
place	NULL
.	NULL

Incubations	NULL
containing	NULL
cytosol	NULL
(	NULL
50	NULL
to	NULL
90	NULL
%	NULL
by	NULL
volume	NULL
)	NULL
and	NULL
other	NULL
additions	NULL
were	NULL
prepared	NULL
as	NULL
noted	NULL
in	NULL
the	NULL
legends	NULL
to	NULL
the	NULL
figures	NULL
and	NULL
tables	NULL
.	NULL

Steroid-binding	NULL
capacity	NULL
was	NULL
assayed	NULL
by	NULL
removing	NULL
0.36-ml	NULL
aliquots	NULL
of	NULL
the	NULL
incubation	NULL
mix	NULL
and	NULL
incubating	NULL
them	NULL
for	NULL
2	NULL
h	NULL
at	NULL
0°C	NULL
in	NULL
a	NULL
total	NULL
volume	NULL
of	NULL
0.40	NULL
ral	NULL
with	NULL
50	NULL
nm	NULL
[	NULL
*H	NULL
]	NULL
triamcinolone	NULL
acetonide	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
either	NULL
a	NULL
1000-fold	NULL
excess	NULL
of	NULL
nonradioactive	NULL
dexamethasone	NULL
or	NULL
vehicle	NULL
as	NULL
previously	NULL
described	NULL
.	NULL

This	NULL
concentration	NULL
of	NULL
[	NULL
'	NULL
H	NULL
Itriamcinolone	NULL
acetonide	NULL
is	NULL
5	NULL
times	NULL
the	NULL
concentration	NULL
required	NULL
to	NULL
saturate	NULL
specific	NULL
binding	NULL
sites	NULL
on	NULL
long	NULL
term	NULL
incubation	NULL
at	NULL
0°C	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
)	NULL
and	NULL
,	NULL
at	NULL
this	NULL
high	NULL
steroid	NULL
concentration	NULL
,	NULL
binding	NULL
sites	NULL
are	NULL
saturated	NULL
in	NULL
2	NULL
h	NULL
(	NULL
17	NULL
)	NULL
.	NULL

Bound	NULL
steroid	NULL
was	NULL
separated	NULL
from	NULL
free	NULL
material	NULL
by	NULL
chroma-tography	NULL
on	NULL
small	NULL
columns	NULL
of	NULL
Sephadex	NULL
G-25	NULL
and	NULL
bound	NULL
radioactivity	NULL
was	NULL
assayed	NULL
as	NULL
described	NULL
before	NULL
(	NULL
18	NULL
)	NULL
.	NULL

The	NULL
specific	NULL
binding	NULL
capacity	NULL
represents	NULL
the	NULL
bound	NULL
counts	NULL
per	NULL
min	NULL
measured	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
dexamethasone	NULL
minus	NULL
that	NULL
measured	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
competing	NULL
steroid	NULL
.	NULL

All	NULL
binding	NULL
values	NULL
presented	NULL
in	NULL
this	NULL
paper	NULL
represent	NULL
the	NULL
average	NULL
of	NULL
duplicate	NULL
determinations	NULL
.	NULL

Experiments	NULL
Involving	NULL
Inhibition	NULL
of	NULL
Metabolism	NULL
of	NULL
Intact	NULL
Cells-IM-9	NULL
cells	NULL
were	NULL
harvested	NULL
from	NULL
log	NULL
phase	NULL
cultures	NULL
by	NULL
low	NULL
speed	NULL
centrifugation	NULL
and	NULL
resuspended	NULL
at	NULL
37°C	NULL
in	NULL
glucose-free	NULL
RPMI	NULL
1640	NULL
(	NULL
Roswell	NULL
Park	NULL
Memorial	NULL
Institute	NULL
)	NULL
medium	NULL
containing	NULL
4.5	NULL
g	NULL
liter	NULL
of	NULL
bovine	NULL
serum	NULL
albumin	NULL
at	NULL
a	NULL
cell	NULL
concentration	NULL
of	NULL
2	NULL
to	NULL
4	NULL
X	NULL
10°	NULL
cells/ml	NULL
.	NULL

The	NULL
100-ml	NULL
cultures	NULL
in	NULL
Blake	NULL
bottles	NULL
were	NULL
either	NULL
continuously	NULL
perfused	NULL
by	NULL
passing	NULL
95	NULL
%	NULL
nitrogen	NULL
,	NULL
5	NULL
%	NULL
CO	NULL
;	NULL
over	NULL
the	NULL
surface	NULL
of	NULL
the	NULL
culture	NULL
medium	NULL
at	NULL
a	NULL
rate	NULL
of	NULL
1	NULL
liter/min/culture	NULL
or	NULL
perfused	NULL
for	NULL
3	NULL
min	NULL
with	NULL
5	NULL
%	NULL
CO	NULL
;	NULL
and	NULL
air	NULL
and	NULL
sealed	NULL
.	NULL

In	NULL
some	NULL
experiments	NULL
,	NULL
the	NULL
oxygen	NULL
tension	NULL
and	NULL
pH	NULL
of	NULL
the	NULL
culture	NULL
medium	NULL
was	NULL
determined	NULL
with	NULL
an	NULL
International	NULL
IL	NULL
435	NULL
313	NULL
blood	NULL
gas	NULL
analyzer	NULL
and	NULL
the	NULL
oxygen	NULL
concentration	NULL
in	NULL
the	NULL
gas	NULL
phase	NULL
was	NULL
determined	NULL
with	NULL
a	NULL
Perkin-Elmer	NULL
respiratory	NULL
mass	NULL
spectrometer	NULL
.	NULL

Cultures	NULL
were	NULL
maintained	NULL
at	NULL
37°C	NULL
until	NULL
,	NULL
at	NULL
various	NULL
times	NULL
as	NULL
indicated	NULL
,	NULL
they	NULL
were	NULL
rapidly	NULL
poured	NULL
into	NULL
a	NULL
250-ml	NULL
!	NULL

centrifuge	NULL
bottle	NULL
and	NULL
immediately	NULL
cooled	NULL
by	NULL
immersion	NULL
into	NULL
a	NULL
dry	NULL
ice/acetone	NULL
bath	NULL
.	NULL

After	NULL
rapid	NULL
cooling	NULL
,	NULL
they	NULL
were	NULL
placed	NULL
in	NULL
an	NULL
ice	NULL
bath	NULL
and	NULL
all	NULL
subsequent	NULL
procedures	NULL
were	NULL
carried	NULL
out	NULL
at	NULL
0°C	NULL
.	NULL

Each	NULL
Blake	NULL
bottle	NULL
was	NULL
rinsed	NULL
once	NULL
with	NULL
20	NULL
mi	NULL
of	NULL
iced	NULL
normal	NULL
saline	NULL
and	NULL
the	NULL
wash	NULL
was	NULL
added	NULL
to	NULL
the	NULL
cooled	NULL
cell	NULL
suspension	NULL
.	NULL

Twenty-five	NULL
milliliters	NULL
of	NULL
each	NULL
culture	NULL
was	NULL
removed	NULL
for	NULL
ATP	NULL
assay	NULL
as	NULL
described	NULL
below	NULL
and	NULL
che	NULL
remaining	NULL
95	NULL
ml	NULL
was	NULL
utilized	NULL
for	NULL
assay	NULL
of	NULL
glucocorticoid-binding	NULL
capacity	NULL
.	NULL

This	NULL
portion	NULL
was	NULL
centrifuged	NULL
at	NULL
low	NULL
speed	NULL
,	NULL
in	NULL
a	NULL
graduated	NULL
conical	NULL
centrifuge	NULL
tube	NULL
.	NULL

Two	NULL
milliliters	NULL
of	NULL
the	NULL
hypotonic	NULL
buffer	NULL
was	NULL
added	NULL
to	NULL
each	NULL
0.4-	NULL
to	NULL
0.6-ml	NULL
packed	NULL
cell	NULL
pellet	NULL
and	NULL
was	NULL
either	NULL
ruptured	NULL
and	NULL
assayed	NULL
for	NULL
binding	NULL
immediately	NULL
or	NULL
frozen	NULL
at	NULL
-~70°C	NULL
for	NULL
subsequent	NULL
binding	NULL
assay	NULL
.	NULL

There	NULL
was	NULL
no	NULL
loss	NULL
of	NULL
binding	NULL
capacity	NULL
over	NULL
2	NULL
weeks	NULL
of	NULL
storage	NULL
at	NULL
-70°C	NULL
.	NULL

After	NULL
suspension	NULL
in	NULL
hypotonic	NULL
buffer	NULL
or	NULL
after	NULL
rapid	NULL
thawing	NULL
as	NULL
described	NULL
above	NULL
,	NULL
cells	NULL
were	NULL
homogenized	NULL
with	NULL
several	NULL
strokes	NULL
of	NULL
a	NULL
Dounce	NULL
homogenizer	NULL
and	NULL
centrifuged	NULL
at	NULL
25,000	NULL
x	NULL
g.	NULL
Specific	NULL
binding	NULL
capacity	NULL
was	NULL
determined	NULL
in	NULL
duplicate	NULL
0.4-ml	NULL
samples	NULL
of	NULL
this	NULL
27,000	NULL
x	NULL
g	NULL
supernatant	NULL
rather	NULL
than	NULL
in	NULL
a	NULL
high	NULL
speed	NULL
(	NULL
100,000	NULL
x	NULL
g	NULL
)	NULL
cytosol	NULL
.	NULL

Aliquots	NULL
of	NULL
each	NULL
27,000	NULL
x	NULL
g	NULL
supernatant	NULL
were	NULL
assayed	NULL
for	NULL
protein	NULL
content	NULL
according	NULL
to	NULL
the	NULL
method	NULL
of	NULL
Oyama	NULL
and	NULL
Eagle	NULL
(	NULL
19	NULL
)	NULL
,	NULL
using	NULL
bovine	NULL
serum	NULL
albumin	NULL
(	NULL
Sigma	NULL
,	NULL
Fraction	NULL
V	NULL
)	NULL
as	NULL
a	NULL
reference	NULL
standard	NULL
.	NULL

Incorporation	NULL
of	NULL
[	NULL
*H	NULL
]	NULL
leucine	NULL
into	NULL
acid-insoluble	NULL
form	NULL
was	NULL
assayed	NULL
by	NULL
adding	NULL
5	NULL
Ci	NULL
of	NULL
the	NULL
labeled	NULL
amino	NULL
acid/ml	NULL
of	NULL
suspension	NULL
of	NULL
IM-9	NULL
cells	NULL
(	NULL
2	NULL
x	NULL
10°	NULL
cells/ml	NULL
in	NULL
30-ml	NULL
suspensions	NULL
)	NULL
in	NULL
RPMI	NULL
medium	NULL
which	NULL
contains	NULL
0.4	NULL
mM	NULL
nonradioactive	NULL
leucine	NULL
.	NULL

Cycloheximide	NULL
was	NULL
added	NULL
in	NULL
0.01	NULL
volume	NULL
of	NULL
aqueous	NULL
solution	NULL
to	NULL
a	NULL
final	NULL
concentration	NULL
of	NULL
5	NULL
ug/ml	NULL
.	NULL

Aliquots	NULL
(	NULL
2.0	NULL
ml	NULL
)	NULL
of	NULL
triplicate	NULL
cell	NULL
suspensions	NULL
were	NULL
removed	NULL
,	NULL
precipitated	NULL
with	NULL
cold	NULL
10	NULL
%	NULL
trichloroacetic	NULL
acid	NULL
,	NULL
washed	NULL
,	NULL
filtered	NULL
,	NULL
and	NULL
assayed	NULL
for	NULL
radioactivity	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
20	NULL
)	NULL
.	NULL

ATP	NULL
Assays-After	NULL
removing	NULL
an	NULL
aliquot	NULL
for	NULL
determining	NULL
cell	NULL
count	NULL
,	NULL
the	NULL
25-ral	NULL
cell	NULL
suspensions	NULL
were	NULL
centrifuged	NULL
at	NULL
low	NULL
speed	NULL
and	NULL
the	NULL
pellet	NULL
was	NULL
resuspended	NULL
in	NULL
0.4	NULL
to	NULL
0.6	NULL
ml	NULL
of	NULL
0.6	NULL
M	NULL
perchloric	NULL
acid	NULL
,	NULL
mixed	NULL
,	NULL
and	NULL
centrifuged	NULL
at	NULL
2,000	NULL
x	NULL
g	NULL
for	NULL
15	NULL
min	NULL
.	NULL

The	NULL
supernatant	NULL
was	NULL
neutralized	NULL
with	NULL
2	NULL
M	NULL
potassium	NULL
carbonate	NULL
,	NULL
incubated	NULL
at	NULL
0°C	NULL
for	NULL
30	NULL
min	NULL
,	NULL
centrifuged	NULL
again	NULL
for	NULL
5	NULL
min	NULL
,	NULL
and	NULL
the	NULL
supernatant	NULL
was	NULL
stored	NULL
at	NULL
-70°C	NULL
.	NULL

We	NULL
have	NULL
found	NULL
that	NULL
the	NULL
luciferin-luciferase	NULL
assay	NULL
for	NULL
ATP	NULL
which	NULL
we	NULL
have	NULL
previously	NULL
used	NULL
with	NULL
cytosols	NULL
prepared	NULL
from	NULL
mouse	NULL
L-cells	NULL
(	NULL
11	NULL
)	NULL
does	NULL
not	NULL
give	NULL
reliable	NULL
results	NULL
with	NULL
cytosol	NULL
prepared	NULL
from	NULL
IM-9	NULL
cells	NULL
;	NULL
consequently	NULL
we	NULL
have	NULL
assayed	NULL
ATP	NULL
using	NULL
an	NULL
enzyme	NULL
assay	NULL
coupled	NULL
to	NULL
the	NULL
fluorometric	NULL
measurement	NULL
of	NULL
reduced	NULL
nicotinamide	NULL
adenine	NULL
nucleotides	NULL
(	NULL
21	NULL
)	NULL
as	NULL
described	NULL
by	NULL
Marks	NULL
and	NULL
Medzihradsky	NULL
(	NULL
22	NULL
)	NULL
.	NULL

Neutralized	NULL
perchlorate	NULL
supernatant	NULL
(	NULL
5	NULL
to	NULL
20	NULL
ul	NULL
)	NULL
was	NULL
added	NULL
to	NULL
a	NULL
reaction	NULL
mixture	NULL
(	NULL
final	NULL
volume	NULL
,	NULL
1.0	NULL
ml	NULL
)	NULL
containing	NULL
a	NULL
final	NULL
concentration	NULL
of	NULL
50	NULL
mM	NULL
Tris-HCl	NULL
buffer	NULL
(	NULL
pH	NULL
7.5	NULL
)	NULL
,	NULL
1	NULL
mm	NULL
MgCl	NULL
»	NULL
,	NULL
0.05	NULL
my	NULL
NADP*	NULL
,	NULL
0.5	NULL
mm	NULL
dithiothreitol	NULL
,	NULL
0.1	NULL
mm	NULL
glucose	NULL
,	NULL
0.02	NULL
%	NULL
bovine	NULL
serum	NULL
albumin	NULL
,	NULL
0.1	NULL
ug/ml	NULL
of	NULL
glucose-6-phosphate	NULL
dehydrogenase	NULL
and	NULL
1	NULL
ug/ml	NULL
of	NULL
hexokinase	NULL
.	NULL

NADPH	NULL
was	NULL
assayed	NULL
in	NULL
a	NULL
fluorometer	NULL
at	NULL
excitation	NULL
and	NULL
emission	NULL
wavelengths	NULL
of	NULL
360	NULL
and	NULL
470	NULL
nm	NULL
,	NULL
respectively	NULL
.	NULL

Standard	NULL
curves	NULL
were	NULL
run	NULL
with	NULL
each	NULL
assay	NULL
and	NULL
ATP	NULL
content	NULL
was	NULL
expressed	NULL
as	NULL
nanomoles	NULL
of	NULL
ATP/10°	NULL
cells	NULL
.	NULL

RESULTS	NULL
In	NULL
order	NULL
to	NULL
carry	NULL
out	NULL
the	NULL
intact	NULL
cell	NULL
experiments	NULL
to	NULL
be	NULL
reported	NULL
here	NULL
,	NULL
we	NULL
required	NULL
a	NULL
source	NULL
of	NULL
cells	NULL
that	NULL
would	NULL
be	NULL
available	NULL
in	NULL
large	NULL
amounts	NULL
,	NULL
that	NULL
could	NULL
be	NULL
suspended	NULL
at	NULL
high	NULL
density	NULL
and	NULL
maintain	NULL
viability	NULL
over	NULL
several	NULL
hours	NULL
,	NULL
and	NULL
that	NULL
contain	NULL
a	NULL
high	NULL
receptor	NULL
activity	NULL
.	NULL

Therefore	NULL
,	NULL
we	NULL
have	NULL
examined	NULL
several	NULL
lines	NULL
of	NULL
human	NULL
B	NULL
lymphocytes	NULL
maintained	NULL
in	NULL
continuous	NULL
culture	NULL
for	NULL
their	NULL
glucocorticoid	NULL
sensitivity	NULL
in	NULL
terms	NULL
of	NULL
growth	NULL
inhibition	NULL
and	NULL
for	NULL
their	NULL
ability	NULL
to	NULL
bind	NULL
radiolabeled	NULL
triamcinolone	NULL
acetonide	NULL
in	NULL
a	NULL
stereospecific	NULL
manner	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Table	NULL
I	NULL
,	NULL
neither	NULL
the	NULL
Burkitt	NULL
nor	NULL
the	NULL
IM-9	NULL
cells	NULL
had	NULL
any	NULL
substantial	NULL
cytolytic	NULL
response	NULL
to	NULL
glucocorticoid	NULL
as	NULL
assayed	NULL
by	NULL
dye	NULL
exclusion	NULL
viability	NULL
.	NULL

Indeed	NULL
,	NULL
only	NULL
one	NULL
of	NULL
the	NULL
lines	NULL
,	NULL
Burkitt	NULL
EB-3	NULL
cells	NULL
,	NULL
demonstrated	NULL
significant	NULL
growth	NULL
inhibition	NULL
.	NULL

Cytosols	NULL
prepared	NULL
from	NULL
Burkitt	NULL
cells	NULL
had	NULL
low	NULL
specific	NULL
binding	NULL
activity	NULL
that	NULL
could	NULL
not	NULL
be	NULL
substantially	NULL
enhanced	NULL
by	NULL
dithiothreitol	NULL
and	NULL
molybdate	NULL
(	NULL
Table	NULL
I	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
IM-9	NULL
cells	NULL
have	NULL
a	NULL
high	NULL
glucocorticoid	NULL
binding	NULL
capacity	NULL
that	NULL
is	NULL
about	NULL
4	NULL
times	NULL
that	NULL
reported	NULL
for	NULL
similar	NULL
cytosols	NULL
prepared	NULL
from	NULL
the	NULL
very	NULL
sensitive	NULL
C7	NULL
subclone	NULL
of	NULL
the	NULL
CEM	NULL
human	NULL
lympho-blast	NULL
line	NULL
(	NULL
23	NULL
)	NULL
.	NULL

Although	NULL
the	NULL
IM-9	NULL
cells	NULL
demonstrate	NULL
no	NULL
growth	NULL
436	NULL
Glucocorticoid	NULL
Receptor	NULL
Activation	NULL
and	NULL
Inactivation	NULL
I	NULL
Effect	NULL
of	NULL
glucocorticoid	NULL
on	NULL
the	NULL
growth	NULL
and	NULL
viability	NULL
of	NULL
cultured	NULL
human	NULL
B	NULL
lymphocytes	NULL
and	NULL
specific	NULL
binding	NULL
of	NULL
cytosol	NULL
preparations	NULL
Replicate	NULL
cultures	NULL
of	NULL
the	NULL
indicated	NULL
lines	NULL
of	NULL
cultured	NULL
human	NULL
lymphocytes	NULL
were	NULL
set	NULL
up	NULL
at	NULL
5	NULL
x	NULL
10°	NULL
cells/ml	NULL
and	NULL
incubated	NULL
for	NULL
5	NULL
days	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
0.1	NULL
um	NULL
triamcinolone	NULL
acetonide	NULL
(	NULL
Burkitt	NULL
cells	NULL
)	NULL
,	NULL
10	NULL
uM	NULL
dexamethasone	NULL
(	NULL
IM-9	NULL
)	NULL
,	NULL
or	NULL
ethanol	NULL
vehicle	NULL
.	NULL

After	NULL
5	NULL
days	NULL
,	NULL
cells	NULL
were	NULL
counted	NULL
in	NULL
a	NULL
Coulter	NULL
Counter	NULL
and	NULL
erythrocin	NULL
B	NULL
dye	NULL
exclusion	NULL
indices	NULL
were	NULL
determined	NULL
(	NULL
per	NULL
cent	NULL
values	NULL
expressed	NULL
in	NULL
parentheses	NULL
)	NULL
.	NULL

Each	NULL
cell	NULL
count	NULL
represents	NULL
the	NULL
mean	NULL
and	NULL
standard	NULL
deviation	NULL
of	NULL
three	NULL
replicate	NULL
cultures	NULL
.	NULL

Specific	NULL
binding	NULL
capacity	NULL
was	NULL
assayed	NULL
in	NULL
aliquots	NULL
of	NULL
100,000	NULL
Cell	NULL
count	NULL
and	NULL
viability	NULL
Cell	NULL
line	NULL
Control	NULL
With	NULL
steroid	NULL
cells/ml	NULL
x	NULL
10~°	NULL
Burkitt	NULL
PJ	NULL
2.28	NULL
+	NULL
0.01	NULL
2.30	NULL
+	NULL
0.02	NULL
(	NULL
92	NULL
)	NULL
(	NULL
90	NULL
)	NULL
Burkitt	NULL
Raji	NULL
1.67	NULL
+	NULL
0.06	NULL
1.31	NULL
+	NULL
0.03	NULL
(	NULL
98	NULL
)	NULL
(	NULL
96	NULL
)	NULL
Burkitt	NULL
EB-3	NULL
1.38	NULL
+	NULL
0.01	NULL
0.64	NULL
+	NULL
0.01	NULL
(	NULL
97	NULL
)	NULL
(	NULL
95	NULL
)	NULL
Burkitt	NULL
Jijoye	NULL
1.33	NULL
+	NULL
0.07	NULL
1.39	NULL
+	NULL
0.07	NULL
(	NULL
96	NULL
)	NULL
(	NULL
95	NULL
)	NULL
IM-9	NULL
2.06	NULL
+	NULL
0.04	NULL
2.19	NULL
+	NULL
0.08	NULL
(	NULL
87	NULL
)	NULL
(	NULL
83	NULL
)	NULL
inhibition	NULL
with	NULL
glucocorticoids	NULL
,	NULL
their	NULL
high	NULL
binding	NULL
capacity	NULL
is	NULL
required	NULL
for	NULL
the	NULL
intact	NULL
cell	NULL
studies	NULL
using	NULL
our	NULL
techniques	NULL
.	NULL

When	NULL
IM-9	NULL
cells	NULL
are	NULL
grown	NULL
in	NULL
200-ml	NULL
cultures	NULL
(	NULL
6-liter	NULL
lots	NULL
were	NULL
grown	NULL
in	NULL
this	NULL
fashion	NULL
so	NULL
that	NULL
large	NULL
amounts	NULL
of	NULL
cells	NULL
would	NULL
be	NULL
available	NULL
for	NULL
preparation	NULL
of	NULL
100,000	NULL
x	NULL
g	NULL
cytosol	NULL
utilized	NULL
in	NULL
the	NULL
experiments	NULL
of	NULL
Figs	NULL
.	NULL

7	NULL
to	NULL
11	NULL
and	NULL
Tables	NULL
II	NULL
and	NULL
III	NULL
)	NULL
,	NULL
the	NULL
binding	NULL
capacity	NULL
is	NULL
somewhat	NULL
lower	NULL
than	NULL
the	NULL
1,530	NULL
fmol/mg	NULL
of	NULL
protein	NULL
presented	NULL
in	NULL
Table	NULL
I	NULL
.	NULL

For	NULL
example	NULL
,	NULL
the	NULL
average	NULL
binding	NULL
capacity	NULL
presented	NULL
in	NULL
the	NULL
100,000	NULL
x	NULL
g	NULL
supernatants	NULL
utilized	NULL
in	NULL
the	NULL
experiments	NULL
to	NULL
be	NULL
presented	NULL
later	NULL
is	NULL
about	NULL
1,250	NULL
fmol/mg	NULL
of	NULL
protein	NULL
.	NULL

From	NULL
experiments	NULL
where	NULL
we	NULL
have	NULL
determined	NULL
the	NULL
amount	NULL
of	NULL
triamcinolone	NULL
acetonide	NULL
bound	NULL
of	NULL
protein	NULL
in	NULL
the	NULL
27,000	NULL
x	NULL
g	NULL
supernatant	NULL
prepared	NULL
from	NULL
a	NULL
known	NULL
number	NULL
of	NULL
cells	NULL
,	NULL
we	NULL
can	NULL
calculate	NULL
that	NULL
there	NULL
are	NULL
about	NULL
30,000	NULL
specific	NULL
binding	NULL
sites/cell	NULL
.	NULL

This	NULL
is	NULL
similar	NULL
to	NULL
the	NULL
number	NULL
of	NULL
binding	NULL
sites	NULL
we	NULL
have	NULL
calculated	NULL
for	NULL
L929	NULL
mouse	NULL
fibroblasts	NULL
growing	NULL
in	NULL
suspension	NULL
culture	NULL
(	NULL
24	NULL
)	NULL
.	NULL

Alteration	NULL
of	NULL
Receptor	NULL
Activity	NULL
in	NULL
Intact	NULL
Cells-When	NULL
IM-9	NULL
cells	NULL
suspended	NULL
in	NULL
growth	NULL
medium	NULL
are	NULL
perfused	NULL
with	NULL
nitrogen	NULL
,	NULL
the	NULL
oxygen	NULL
tension	NULL
of	NULL
the	NULL
medium	NULL
drops	NULL
rapidly	NULL
(	NULL
Fig	NULL
.	NULL

1A	NULL
)	NULL
but	NULL
there	NULL
is	NULL
only	NULL
a	NULL
minimal	NULL
effect	NULL
on	NULL
cellular	NULL
ATP	NULL
content	NULL
over	NULL
the	NULL
course	NULL
of	NULL
3	NULL
h	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
)	NULL
.	NULL

It	NULL
is	NULL
clear	NULL
from	NULL
the	NULL
data	NULL
of	NULL
Fig	NULL
.	NULL

1B	NULL
that	NULL
cells	NULL
must	NULL
be	NULL
deprived	NULL
of	NULL
both	NULL
glucose	NULL
and	NULL
oxygen	NULL
in	NULL
order	NULL
for	NULL
the	NULL
ATP	NULL
content	NULL
to	NULL
be	NULL
lowered	NULL
rapidly	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

24	NULL
,	NULL
cells	NULL
suspended	NULL
in	NULL
glucose-free	NULL
medium	NULL
in	NULL
a	NULL
nitrogen	NULL
atmosphere	NULL
lose	NULL
their	NULL
ability	NULL
to	NULL
bind	NULL
glucocorticoids	NULL
.	NULL

It	NULL
should	NULL
be	NULL
noted	NULL
that	NULL
the	NULL
cells	NULL
are	NULL
not	NULL
being	NULL
exposed	NULL
to	NULL
steroids	NULL
during	NULL
the	NULL
inactivation	NULL
process	NULL
.	NULL

Rather	NULL
,	NULL
the	NULL
27,000	NULL
x	NULL
g	NULL
supernatant	NULL
is	NULL
being	NULL
prepared	NULL
from	NULL
cells	NULL
that	NULL
have	NULL
been	NULL
exposed	NULL
to	NULL
energy-limiting	NULL
conditions	NULL
for	NULL
various	NULL
periods	NULL
of	NULL
time	NULL
and	NULL
it	NULL
is	NULL
then	NULL
incubated	NULL
with	NULL
[	NULL
°H	NULL
Jtriamcinolone	NULL
acetonide	NULL
at	NULL
0°C	NULL
to	NULL
assay	NULL
binding	NULL
capacity	NULL
,	NULL
Thus	NULL
,	NULL
the	NULL
decrease	NULL
in	NULL
binding	NULL
represents	NULL
inactivation	NULL
or	NULL
degradation	NULL
of	NULL
unoccupied	NULL
receptor	NULL
.	NULL

The	NULL
loss	NULL
of	NULL
binding	NULL
capacity	NULL
coincides	NULL
roughly	NULL
with	NULL
the	NULL
decrease	NULL
in	NULL
ATP	NULL
content	NULL
.	NULL

The	NULL
binding	NULL
capacity	NULL
of	NULL
cells	NULL
incubated	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
glucose	NULL
and	NULL
air	NULL
is	NULL
compared	NULL
with	NULL
that	NULL
of	NULL
cells	NULL
incubated	NULL
under	NULL
energy-limiting	NULL
conditions	NULL
in	NULL
Fig	NULL
.	NULL

2B	NULL
.	NULL

In	NULL
the	NULL
presence	NULL
of	NULL
glucose	NULL
and	NULL
oxygen	NULL
,	NULL
the	NULL
specific	NULL
binding	NULL
capacity	NULL
can	NULL
be	NULL
maintained	NULL
for	NULL
several	NULL
hours	NULL
.	NULL

Addition	NULL
of	NULL
3	NULL
mm	NULL
sodium	NULL
molybdate	NULL
to	NULL
the	NULL
suspension	NULL
medium	NULL
does	NULL
not	NULL
affect	NULL
either	NULL
the	NULL
steady	NULL
state	NULL
binding	NULL
capacity	NULL
or	NULL
the	NULL
rate	NULL
of	NULL
loss	NULL
under	NULL
metabolic	NULL
restriction	NULL
.	NULL

x	NULL
g	NULL
supernatants	NULL
prepared	NULL
from	NULL
cells	NULL
harvested	NULL
in	NULL
log	NULL
phase	NULL
.	NULL

Each	NULL
binding	NULL
value	NULL
for	NULL
cytosol	NULL
alone	NULL
represents	NULL
the	NULL
average	NULL
of	NULL
at	NULL
least	NULL
four	NULL
assays	NULL
from	NULL
two	NULL
or	NULL
more	NULL
cytosol	NULL
preparations	NULL
expressed	NULL
as	NULL
femtomoles	NULL
of	NULL
[	NULL
°H	NULL
Itriamcinolone	NULL
acetonide	NULL
bound	NULL
specifically	NULL
per	NULL
mg	NULL
of	NULL
protein	NULL
+	NULL
the	NULL
standard	NULL
deviation	NULL
.	NULL

In	NULL
each	NULL
case	NULL
,	NULL
binding	NULL
assays	NULL
were	NULL
also	NULL
performed	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
2	NULL
mM	NULL
dithiothreitol	NULL
and	NULL
10	NULL
mm	NULL
sodium	NULL
molybdate	NULL
and	NULL
those	NULL
values	NULL
for	NULL
Burkitt	NULL
cells	NULL
represent	NULL
the	NULL
average	NULL
of	NULL
duplicate	NULL
determinations	NULL
.	NULL

Specific	NULL
binding	NULL
capacity	NULL
of	NULL
cytosol	NULL
Ratio	NULL
of	NULL
steroid	NULL
treated	NULL
to	NULL
con-	NULL
Cytosol	NULL
plus	NULL
dithio-	NULL
Cytosol	NULL
alone	NULL
threitol	NULL
and	NULL
MoO	NULL
,	NULL
trol	NULL
fmol/mg	NULL
protein	NULL
1.01	NULL
118	NULL
+	NULL
6	NULL
155	NULL
0.78	NULL
168	NULL
+	NULL
34	NULL
202	NULL
0.46	NULL
194	NULL
+	NULL
23	NULL
257	NULL
1.05	NULL
305	NULL
+	NULL
37	NULL
496	NULL
1.06	NULL
1530	NULL
+	NULL
325	NULL
1480	NULL
+	NULL
94	NULL
$	NULL
-___	NULL
«	NULL
f	NULL
B	NULL
l/Wz	NULL
+6lo	NULL
Tl	NULL
€	NULL
a	NULL
/	NULL
-	NULL
O2	NULL
+	NULL
Glu	NULL
E	NULL
B3+/T\	NULL
|	NULL
E	NULL
6	NULL
\	NULL
$	NULL
z	NULL
C	NULL
o	NULL
6	NULL
<	NULL
.	NULL

+02	NULL
-Glu	NULL
Prs	NULL
w	NULL
£2	NULL
g	NULL
ar	NULL
a	NULL
€	NULL
}	NULL
©	NULL
>	NULL
5	NULL
t	NULL
F	NULL
\	NULL
&	NULL
Eop	NULL
A	NULL
{	NULL
>	NULL
<	NULL
%	NULL
-02~Glu\¢	NULL
0	NULL
Og	NULL
~-	NULL
t	NULL
2	NULL
3	NULL
PERFUSION	NULL
TIME	NULL
(	NULL
hours	NULL
)	NULL
INCUBATION	NULL
TIME	NULL
(	NULL
hours	NULL
)	NULL
Fic	NULL
.	NULL

1	NULL
.	NULL

Effect	NULL
of	NULL
hypoxia	NULL
and	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
glucose	NULL
on	NULL
IM-9	NULL
cell	NULL
ATP	NULL
content	NULL
.	NULL

A	NULL
,	NULL
IM-9	NULL
cell	NULL
cultures	NULL
were	NULL
continuously	NULL
perfused	NULL
with	NULL
an	NULL
atmosphere	NULL
of	NULL
95	NULL
%	NULL
nitrogen	NULL
,	NULL
5	NULL
%	NULL
CO	NULL
»	NULL
.	NULL

At	NULL
the	NULL
indicated	NULL
times	NULL
,	NULL
samples	NULL
of	NULL
the	NULL
medium	NULL
(	NULL
@	NULL
)	NULL
and	NULL
the	NULL
gas	NULL
phase	NULL
(	NULL
OQ	NULL
)	NULL
were	NULL
removed	NULL
with	NULL
a	NULL
sealed	NULL
syringe	NULL
and	NULL
assayed	NULL
for	NULL
oxygen	NULL
content	NULL
as	NULL
described	NULL
under	NULL
``	NULL
Methods	NULL
.	NULL
``	NULL

B	NULL
,	NULL
IM-9	NULL
cells	NULL
were	NULL
harvested	NULL
from	NULL
culture	NULL
and	NULL
suspended	NULL
in	NULL
RPMI	NULL
medium	NULL
without	NULL
glucose	NULL
,	NULL
the	NULL
suspension	NULL
was	NULL
divided	NULL
into	NULL
several	NULL
portions	NULL
,	NULL
and	NULL
incubated	NULL
at	NULL
37°C	NULL
under	NULL
the	NULL
following	NULL
conditions	NULL
:	NULL
@	NULL
,	NULL
plus	NULL
glucose	NULL
in	NULL
an	NULL
atmosphere	NULL
of	NULL
air	NULL
;	NULL
O	NULL
,	NULL
plus	NULL
glucose	NULL
in	NULL
an	NULL
atmosphere	NULL
of	NULL
nitrogen	NULL
;	NULL
A	NULL
,	NULL
minus	NULL
glucose	NULL
in	NULL
air	NULL
;	NULL
A	NULL
,	NULL
minus	NULL
glucose	NULL
in	NULL
nitrogen	NULL
.	NULL

At	NULL
the	NULL
indicated	NULL
times	NULL
,	NULL
samples	NULL
of	NULL
cell	NULL
suspension	NULL
were	NULL
removed	NULL
and	NULL
assayed	NULL
for	NULL
ATP	NULL
.	NULL

ATP	NULL
content	NULL
represents	NULL
the	NULL
mean	NULL
of	NULL
values	NULL
determined	NULL
from	NULL
three	NULL
cell	NULL
suspensions	NULL
expressed	NULL
as	NULL
nanomoles	NULL
of	NULL
ATP/10°	NULL
cells	NULL
and	NULL
the	NULL
error	NULL
bars	NULL
represent	NULL
the	NULL
standard	NULL
deviation	NULL
from	NULL
the	NULL
mean	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
when	NULL
glucose	NULL
is	NULL
added	NULL
to	NULL
cells	NULL
that	NULL
have	NULL
been	NULL
exposed	NULL
to	NULL
metabolic	NULL
restriction	NULL
and	NULL
the	NULL
cells	NULL
are	NULL
returned	NULL
to	NULL
an	NULL
air	NULL
atmosphere	NULL
,	NULL
both	NULL
specific	NULL
binding	NULL
capacity	NULL
and	NULL
ATP	NULL
levels	NULL
rise	NULL
.	NULL

The	NULL
extent	NULL
of	NULL
reactivation	NULL
of	NULL
the	NULL
binding	NULL
capacity	NULL
decreases	NULL
with	NULL
time	NULL
of	NULL
incubation	NULL
under	NULL
nitrogen	NULL
with	NULL
glucose-free	NULL
conditions	NULL
.	NULL

Very	NULL
little	NULL
reactivation	NULL
is	NULL
obtained	NULL
after	NULL
3	NULL
h	NULL
,	NULL
whereas	NULL
complete	NULL
restoration	NULL
is	NULL
obtained	NULL
if	NULL
glucose	NULL
and	NULL
oxygen	NULL
are	NULL
reintroduced	NULL
at	NULL
90	NULL
min	NULL
or	NULL
before	NULL
.	NULL

It	NULL
is	NULL
difficult	NULL
to	NULL
determine	NULL
the	NULL
rate	NULL
at	NULL
which	NULL
reactivation	NULL
occurs	NULL
.	NULL

In	NULL
the	NULL
experiment	NULL
in	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
maximum	NULL
restoration	NULL
of	NULL
both	NULL
ATP	NULL
and	NULL
binding	NULL
capacity	NULL
were	NULL
obtained	NULL
within	NULL
10	NULL
min	NULL
.	NULL

The	NULL
restoration	NULL
of	NULL
binding	NULL
capacity	NULL
occurs	NULL
even	NULL
if	NULL
protein	NULL
synthesis	NULL
is	NULL
blocked	NULL
by	NULL
cycloheximide	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

Cycloheximide	NULL
also	NULL
does	NULL
Glucocorticoid	NULL
Receptor	NULL
Activation	NULL
and	NULL
Inactivation	NULL
sg	NULL
A	NULL
E0	NULL
|	NULL
T4	NULL
E	NULL
o-~	NULL
\	NULL
©	NULL
o~	NULL
h	NULL
1	NULL
o	NULL
Fe	NULL
#	NULL
o	NULL
|	NULL
he	NULL
BS	NULL
$	NULL
e	NULL
ss	NULL
Fee	NULL
|\	NULL
1s	NULL
-	NULL
$	NULL
%	NULL
2	NULL
%	NULL
|	NULL
;	NULL
€	NULL
$	NULL
&	NULL
a	NULL
?	NULL

\	NULL
.	NULL

&	NULL
m	NULL
P	NULL
o	NULL
E	NULL
1	NULL
4	NULL
Specific	NULL
o	NULL
£	NULL
Es	NULL
4	NULL
binding	NULL
a	NULL
[	NULL
rae	NULL
8g	NULL
c	NULL
~	NULL
-	NULL
§¢	NULL
to	NULL
0	NULL
I	NULL
w	NULL
a	NULL
.	NULL

©	NULL
%	NULL
e	NULL
a	NULL
©	NULL
©	NULL
'	NULL
g	NULL
Ne*~e	NULL
,	NULL
6	NULL
``	NULL
5..	NULL
L.o	NULL
>	NULL
ATP	NULL
'	NULL
o	NULL
0	NULL
0	NULL
I	NULL
2	NULL
3	NULL
TIME	NULL
-	NULL
(	NULL
hours	NULL
)	NULL
TIME	NULL
-	NULL
(	NULL
hours	NULL
)	NULL
Fic	NULL
.	NULL

2	NULL
.	NULL

Inactivation	NULL
of	NULL
glucocorticoid-binding	NULL
capacity	NULL
in	NULL
intact	NULL
IM-9	NULL
cells	NULL
.	NULL

A	NULL
,	NULL
IM-9	NULL
cell	NULL
suspensions	NULL
were	NULL
incubated	NULL
at	NULL
37°C	NULL
in	NULL
glucose-free	NULL
medium	NULL
with	NULL
nitrogen	NULL
perfusion	NULL
.	NULL

At	NULL
the	NULL
indicated	NULL
times	NULL
,	NULL
cell	NULL
suspensions	NULL
were	NULL
rapidly	NULL
cooled	NULL
and	NULL
assayed	NULL
for	NULL
glucocorticoid-binding	NULL
capacity	NULL
(	NULL
@	NULL
)	NULL
and	NULL
ATP	NULL
(	NULL
O	NULL
)	NULL
as	NULL
described	NULL
under	NULL
``	NULL
Methods	NULL
.	NULL
``	NULL

B	NULL
,	NULL
IM-9	NULL
cell	NULL
suspensions	NULL
were	NULL
incubated	NULL
under	NULL
the	NULL
following	NULL
conditions	NULL
:	NULL
O	NULL
,	NULL
plus	NULL
glucose	NULL
in	NULL
an	NULL
atmosphere	NULL
of	NULL
air	NULL
;	NULL
A	NULL
,	NULL
plus	NULL
glucose	NULL
and	NULL
3	NULL
mM	NULL
sodium	NULL
molybdate	NULL
in	NULL
air	NULL
;	NULL
@	NULL
,	NULL
minus	NULL
glucose	NULL
in	NULL
nitrogen	NULL
;	NULL
A	NULL
,	NULL
minus	NULL
glucose	NULL
,	NULL
plus	NULL
3	NULL
mm	NULL
sodium	NULL
molybdate	NULL
in	NULL
nitrogen	NULL
.	NULL

At	NULL
the	NULL
indicated	NULL
times	NULL
,	NULL
cell	NULL
suspensions	NULL
were	NULL
rapidly	NULL
cooled	NULL
and	NULL
the	NULL
specific	NULL
glucocorticoid-binding	NULL
capacity	NULL
was	NULL
assayed	NULL
.	NULL

6F	NULL
_	NULL
.	NULL

A	NULL
./	NULL
``	NULL
la	NULL
a	NULL
/	NULL
13	NULL
Specific	NULL
h	NULL
_-	NULL
.	NULL

y	NULL
)	NULL
:	NULL
binding	NULL
/	NULL
a	NULL
2	NULL
G.~	NULL
/	NULL
/	NULL
@	NULL
(	NULL
it	NULL
)	NULL
?	NULL

p	NULL
/	NULL
a	NULL
G	NULL
a	NULL
.	NULL

0	NULL
Loo	NULL
/	NULL
A	NULL
brad	NULL
8	NULL
x	NULL
4t	NULL
/	NULL
/	NULL
,	NULL
``	NULL
aat	NULL
&	NULL
e	NULL
/	NULL
/	NULL
/	NULL
a	NULL
>	NULL
o	NULL
®	NULL
{	NULL
Ao	NULL
/	NULL
/	NULL
A12	NULL
8	NULL
2	NULL
9	NULL
/	NULL
2°	NULL
/	NULL
o	NULL
o	NULL
a	NULL
1,2	NULL
€	NULL
2	NULL
9	NULL
L	NULL
5	NULL
m	NULL
E	NULL
L*	NULL
a.	NULL
o	NULL
g	NULL
«	NULL
E	NULL
L5	NULL
s	NULL
2	NULL
<	NULL
aE	NULL
1	NULL
W	NULL
o	NULL
i	NULL
1	NULL
i	NULL
0	NULL
60	NULL
120	NULL
lel	NULL
TIME	NULL
(	NULL
minutes	NULL
)	NULL
Fic	NULL
.	NULL

3	NULL
.	NULL

Reactivation	NULL
of	NULL
glucocorticoid	NULL
binding	NULL
capacity	NULL
.	NULL

IM-9	NULL
cell	NULL
suspensions	NULL
were	NULL
incubated	NULL
in	NULL
glucose-free	NULL
medium	NULL
in	NULL
a	NULL
nitrogen	NULL
atmosphere	NULL
and	NULL
,	NULL
at	NULL
the	NULL
indicated	NULL
times	NULL
,	NULL
cultures	NULL
were	NULL
harvested	NULL
and	NULL
assayed	NULL
for	NULL
glucocorticoid-binding	NULL
capacity	NULL
(	NULL
@	NULL
)	NULL
and	NULL
ATP	NULL
(	NULL
0	NULL
)	NULL
.	NULL

Glucose	NULL
was	NULL
added	NULL
to	NULL
two	NULL
cultures	NULL
that	NULL
were	NULL
incubated	NULL
for	NULL
60	NULL
and	NULL
120	NULL
min	NULL
,	NULL
respectively	NULL
,	NULL
under	NULL
the	NULL
energy-limiting	NULL
conditions	NULL
,	NULL
the	NULL
perfusion	NULL
gas	NULL
was	NULL
changed	NULL
to	NULL
air	NULL
,	NULL
and	NULL
the	NULL
incubation	NULL
was	NULL
continued	NULL
for	NULL
an	NULL
additional	NULL
90	NULL
min	NULL
,	NULL
at	NULL
which	NULL
time	NULL
the	NULL
glucocorticoid-binding	NULL
capacity	NULL
(	NULL
&	NULL
)	NULL
and	NULL
ATP	NULL
content	NULL
(	NULL
A	NULL
)	NULL
of	NULL
the	NULL
cells	NULL
were	NULL
assayed	NULL
.	NULL

not	NULL
affect	NULL
the	NULL
binding	NULL
capacity	NULL
of	NULL
cells	NULL
incubated	NULL
for	NULL
2	NULL
h	NULL
in	NULL
glucose-containing	NULL
medium	NULL
and	NULL
air	NULL
.	NULL

Although	NULL
there	NULL
is	NULL
no	NULL
relationship	NULL
between	NULL
receptor	NULL
activity	NULL
and	NULL
protein	NULL
synthesis	NULL
over	NULL
the	NULL
short	NULL
time	NULL
of	NULL
these	NULL
experiments	NULL
,	NULL
the	NULL
relationship	NULL
between	NULL
specific	NULL
binding	NULL
capacity	NULL
and	NULL
ATP	NULL
is	NULL
clear	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
.	NULL

The	NULL
data	NULL
for	NULL
Fig	NULL
.	NULL

6	NULL
are	NULL
collected	NULL
from	NULL
several	NULL
experiments	NULL
where	NULL
we	NULL
assayed	NULL
both	NULL
ATP	NULL
and	NULL
binding	NULL
capacity	NULL
in	NULL
the	NULL
same	NULL
cell	NULL
suspensions	NULL
after	NULL
various	NULL
times	NULL
of	NULL
incubation	NULL
under	NULL
energy-limiting	NULL
conditions	NULL
,	NULL
after	NULL
similar	NULL
preincubation	NULL
followed	NULL
by	NULL
reactivation	NULL
,	NULL
and	NULL
after	NULL
control	NULL
incubation	NULL
for	NULL
up	NULL
to	NULL
4	NULL
h	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
glucose	NULL
and	NULL
air	NULL
.	NULL

The	NULL
binding	NULL
capacity	NULL
of	NULL
the	NULL
cell	NULL
is	NULL
related	NULL
to	NULL
the	NULL
ATP	NULL
content	NULL
up	NULL
to	NULL
an	NULL
ATP	NULL
level	NULL
of	NULL
2	NULL
to	NULL
3	NULL
nmol/10°	NULL
cells	NULL
,	NULL
at	NULL
which	NULL
point	NULL
no	NULL
further	NULL
increase	NULL
in	NULL
binding	NULL
occurs	NULL
.	NULL

It	NULL
should	NULL
be	NULL
noted	NULL
that	NULL
the	NULL
binding	NULL
capacity	NULL
for	NULL
these	NULL
crude	NULL
27,000	NULL
x	NULL
g	NULL
supernatants	NULL
is	NULL
maximum	NULL
at	NULL
500	NULL
to	NULL
600	NULL
fmol/mg	NULL
of	NULL
protein	NULL
whereas	NULL
somewhat	NULL
higher	NULL
values	NULL
will	NULL
be	NULL
presented	NULL
for	NULL
high	NULL
speed	NULL
(	NULL
100,000	NULL
x	NULL
g	NULL
)	NULL
supernatants	NULL
which	NULL
contain	NULL
less	NULL
protein	NULL
.	NULL

437	NULL
p	NULL
T	NULL
1	NULL
CI	NULL
binding	NULL
i	NULL
\	NULL
&	NULL
42	NULL
Do	NULL
T	NULL
ATP	NULL
(	NULL
nmoles	NULL
/	NULL
10	NULL
cells	NULL
)	NULL
Be	NULL
O	NULL
1	NULL
1	NULL
_L_	NULL
o	NULL
60	NULL
120	NULL
180	NULL
TIME	NULL
(	NULL
minutes	NULL
)	NULL
Fic	NULL
.	NULL

4	NULL
.	NULL

Rapid	NULL
reactivation	NULL
of	NULL
the	NULL
glucocorticoid-binding	NULL
capacity	NULL
.	NULL

IM-9	NULL
cell	NULL
suspensions	NULL
were	NULL
prepared	NULL
in	NULL
glucose-free	NULL
medium	NULL
and	NULL
were	NULL
incubated	NULL
as	NULL
follows	NULL
:	NULL
@	NULL
,	NULL
plus	NULL
glucose	NULL
in	NULL
air	NULL
atmosphere	NULL
;	NULL
RB	NULL
,	NULL
minus	NULL
glucose	NULL
in	NULL
nitrogen	NULL
for	NULL
90	NULL
min	NULL
;	NULL
A	NULL
,	NULL
minus	NULL
glucose	NULL
in	NULL
nitrogen	NULL
for	NULL
90	NULL
min	NULL
,	NULL
then	NULL
glucose	NULL
was	NULL
added	NULL
and	NULL
incubation	NULL
was	NULL
continued	NULL
in	NULL
air	NULL
.	NULL

At	NULL
the	NULL
indicated	NULL
times	NULL
,	NULL
cell	NULL
suspensions	NULL
were	NULL
harvested	NULL
and	NULL
assayed	NULL
for	NULL
specific	NULL
glucocorticoid-binding	NULL
capacity	NULL
(	NULL
solid	NULL
symbols	NULL
)	NULL
and	NULL
ATP	NULL
(	NULL
corresponding	NULL
open	NULL
symbols	NULL
)	NULL
.	NULL

The	NULL
dashed	NULL
lines	NULL
connect	NULL
the	NULL
values	NULL
obtained	NULL
from	NULL
cells	NULL
that	NULL
were	NULL
preincubated	NULL
under	NULL
the	NULL
energy-limiting	NULL
conditions	NULL
and	NULL
then	NULL
reactivated	NULL
by	NULL
addition	NULL
of	NULL
glucose	NULL
and	NULL
air	NULL
.	NULL

SPECIFIC	NULL
BINDING	NULL
CAPACITY	NULL
(	NULL
fmoles/mg	NULL
proteinx10~2	NULL
)	NULL
O	NULL
B	NULL
5	NULL
\	NULL
0	NULL
,	NULL
3F	NULL
Cycloheximide	NULL
addition	NULL
(	NULL
cpm	NULL
[	NULL
106	NULL
cells	NULL
x10	NULL
``	NULL
3	NULL
)	NULL
P	NULL
\o\	NULL
‘	NULL
_	NULL
R	NULL
U	NULL
U	NULL
U	NULL
U	NULL
.|	NULL
SPECIFIC	NULL
BINDING	NULL
CAPACITY	NULL
(	NULL
fmoles/mg	NULL
protein	NULL
x10	NULL
``	NULL
2	NULL
}	NULL
(	NULL
B4	NULL
)	NULL
Leucine	NULL
incorporation	NULL
0	NULL
-	NULL
io	NULL
20	NULL
30	NULL
40	NULL
TIME	NULL
{	NULL
min	NULL
)	NULL
Fic	NULL
.	NULL

5	NULL
.	NULL

Effect	NULL
of	NULL
cycloheximide	NULL
on	NULL
glucocorticoid-binding	NULL
capacity	NULL
.	NULL

A	NULL
,	NULL
IM-9	NULL
cells	NULL
were	NULL
suspended	NULL
in	NULL
glucose-free	NULL
medium	NULL
,	NULL
the	NULL
suspension	NULL
was	NULL
divided	NULL
into	NULL
several	NULL
portions	NULL
,	NULL
additions	NULL
of	NULL
glucose	NULL
and	NULL
cycloheximide	NULL
(	NULL
5	NULL
ug/ml	NULL
)	NULL
were	NULL
made	NULL
,	NULL
the	NULL
incubations	NULL
were	NULL
continued	NULL
at	NULL
37°C	NULL
and	NULL
specific	NULL
glucocorticoid-binding	NULL
was	NULL
assayed	NULL
.	NULL

Bar	NULL
A	NULL
,	NULL
binding	NULL
for	NULL
zero	NULL
time	NULL
control	NULL
;	NULL
Bar	NULL
B	NULL
,	NULL
incubation	NULL
for	NULL
90	NULL
min	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
glucose	NULL
in	NULL
a	NULL
nitrogen	NULL
atmosphere	NULL
;	NULL
Bar	NULL
C	NULL
,	NULL
incubation	NULL
for	NULL
120	NULL
min	NULL
with	NULL
glucose	NULL
in	NULL
air	NULL
;	NULL
Bar	NULL
D	NULL
,	NULL
incubation	NULL
for	NULL
120	NULL
min	NULL
with	NULL
glucose	NULL
and	NULL
cycloheximide	NULL
in	NULL
air	NULL
;	NULL
Bar	NULL
E	NULL
,	NULL
incubation	NULL
for	NULL
90	NULL
min	NULL
without	NULL
glucose	NULL
in	NULL
nitrogen	NULL
,	NULL
followed	NULL
by	NULL
30	NULL
min	NULL
with	NULL
glucose	NULL
in	NULL
air	NULL
;	NULL
Bar	NULL
F	NULL
,	NULL
incubation	NULL
for	NULL
90	NULL
min	NULL
without	NULL
glucose	NULL
in	NULL
nitrogen	NULL
,	NULL
followed	NULL
by	NULL
addition	NULL
of	NULL
glucose	NULL
and	NULL
cycloheximide	NULL
and	NULL
incubation	NULL
for	NULL
30	NULL
min	NULL
in	NULL
air	NULL
.	NULL

Open	NULL
bars	NULL
have	NULL
had	NULL
no	NULL
glucose	NULL
,	NULL
hatched	NULL
bars	NULL
have	NULL
added	NULL
glucose	NULL
,	NULL
and	NULL
stippled	NULL
bars	NULL
have	NULL
had	NULL
both	NULL
glucose	NULL
and	NULL
cycloheximide	NULL
added	NULL
.	NULL

Bars	NULL
A	NULL
,	NULL
C	NULL
,	NULL
and	NULL
D	NULL
represent	NULL
the	NULL
average	NULL
of	NULL
duplicate	NULL
binding	NULL
assays	NULL
performed	NULL
on	NULL
cytosol	NULL
prepared	NULL
from	NULL
single	NULL
incubations	NULL
.	NULL

Bars	NULL
B	NULL
,	NULL
E	NULL
,	NULL
and	NULL
F	NULL
represent	NULL
the	NULL
average	NULL
of	NULL
assays	NULL
performed	NULL
in	NULL
duplicate	NULL
on	NULL
two	NULL
separate	NULL
incubations	NULL
with	NULL
the	NULL
range	NULL
of	NULL
the	NULL
two	NULL
values	NULL
shown	NULL
by	NULL
the	NULL
line	NULL
at	NULL
the	NULL
top	NULL
of	NULL
the	NULL
bar	NULL
.	NULL

B	NULL
,	NULL
replicate	NULL
suspensions	NULL
of	NULL
IM-9	NULL
cells	NULL
in	NULL
RPMI	NULL
medium	NULL
were	NULL
incubated	NULL
at	NULL
37°C	NULL
with	NULL
[	NULL
°HHleucine	NULL
and	NULL
the	NULL
acid	NULL
insoluble	NULL
radioactivity	NULL
was	NULL
assayed	NULL
on	NULL
2.0-ml	NULL
aliquots	NULL
withdrawn	NULL
at	NULL
the	NULL
indicated	NULL
times	NULL
.	NULL

Cycloheximide	NULL
(	NULL
5	NULL
ug/ml	NULL
)	NULL
was	NULL
added	NULL
to	NULL
three	NULL
suspensions	NULL
after	NULL
15	NULL
min	NULL
of	NULL
incubation	NULL
with	NULL
the	NULL
radiolabeled	NULL
amino	NULL
acid	NULL
.	NULL

Each	NULL
value	NULL
represents	NULL
the	NULL
average	NULL
of	NULL
3	NULL
values	NULL
obtained	NULL
from	NULL
replicate	NULL
suspensions	NULL
expressed	NULL
as	NULL
counts	NULL
per	NULL
min	NULL
of	NULL
[	NULL
*H	NULL
]	NULL
leucine	NULL
incorporated/10°	NULL
cells	NULL
.	NULL

O	NULL
,	NULL
controls	NULL
;	NULL
@	NULL
,	NULL
after	NULL
addition	NULL
of	NULL
cycloheximide	NULL
at	NULL
15	NULL
min	NULL
.	NULL

438	NULL
Inactivation	NULL
and	NULL
Stabilization	NULL
of	NULL
Unoccupied	NULL
Receptors	NULL
in	NULL
Cytosol	NULL
Preparations-Prior	NULL
to	NULL
examining	NULL
receptor	NULL
inactivation	NULL
in	NULL
cytosol	NULL
preparations	NULL
,	NULL
we	NULL
wanted	NULL
to	NULL
determine	NULL
whether	NULL
molybdate	NULL
,	NULL
an	NULL
inhibitor	NULL
of	NULL
receptor	NULL
inactivation	NULL
,	NULL
affects	NULL
the	NULL
kinetics	NULL
of	NULL
steroid	NULL
binding	NULL
.	NULL

In	NULL
the	NULL
experiment	NULL
of	NULL
Fig	NULL
.	NULL

7	NULL
,	NULL
replicate	NULL
aliquots	NULL
of	NULL
a	NULL
100,000	NULL
x	NULL
g	NULL
IM-9	NULL
cell	NULL
supernatant	NULL
t	NULL
L	NULL
L	NULL
T	NULL
om	NULL
6t	NULL
1	NULL
{	NULL
o	NULL
S2	NULL
``	NULL
|	NULL
*	NULL
]	NULL
@	NULL
3	NULL
5	NULL
4l	NULL
1	NULL
a	NULL
.	NULL

{	NULL
5	NULL
E°	NULL
o	NULL
$	NULL
4	NULL
11-37	NULL
“	NULL
oE	NULL
(	NULL
|	NULL
.	NULL

wie	NULL
[	NULL
J	NULL
7	NULL
o	NULL
.	NULL

&	NULL
o	NULL
f	NULL
0	NULL
1	NULL
2	NULL
3	NULL
4	NULL
ATP	NULL
(	NULL
nmoles/I0®	NULL
cells	NULL
)	NULL
Fic	NULL
.	NULL

6	NULL
.	NULL

Relationship	NULL
between	NULL
specific	NULL
glucocorticoid-binding	NULL
capacity	NULL
and	NULL
the	NULL
amount	NULL
of	NULL
cellular	NULL
ATP	NULL
.	NULL

The	NULL
specific	NULL
glucocorticoid-binding	NULL
capacity	NULL
assayed	NULL
in	NULL
low	NULL
speed	NULL
(	NULL
27,000	NULL
x	NULL
g	NULL
)	NULL
supernatants	NULL
prepared	NULL
from	NULL
cells	NULL
incubated	NULL
with	NULL
or	NULL
without	NULL
glucose	NULL
and	NULL
oxygen	NULL
has	NULL
been	NULL
plotted	NULL
against	NULL
the	NULL
ATP	NULL
content	NULL
assayed	NULL
in	NULL
the	NULL
same	NULL
cell	NULL
suspensions	NULL
.	NULL

The	NULL
values	NULL
are	NULL
compiled	NULL
from	NULL
several	NULL
different	NULL
experiments	NULL
and	NULL
are	NULL
expressed	NULL
as	NULL
femtomoles	NULL
of	NULL
triamcinolone	NULL
acetonide	NULL
bound	NULL
specifically	NULL
per	NULL
mg	NULL
of	NULL
protein	NULL
versus	NULL
nanomoles	NULL
of	NULL
ATP	NULL
assayed	NULL
per	NULL
10°	NULL
cells	NULL
in	NULL
the	NULL
same	NULL
cell	NULL
aliquot	NULL
.	NULL

The	NULL
solid	NULL
line	NULL
represents	NULL
a	NULL
least	NULL
squares	NULL
regression	NULL
of	NULL
the	NULL
data	NULL
determined	NULL
by	NULL
a	NULL
quadratic	NULL
polynomial	NULL
with	NULL
the	NULL
squared	NULL
term	NULL
in	NULL
ATP	NULL
and	NULL
the	NULL
dashed	NULL
lines	NULL
represent	NULL
the	NULL
95	NULL
%	NULL
confidence	NULL
limits	NULL
for	NULL
the	NULL
regression	NULL
as	NULL
determined	NULL
by	NULL
computer	NULL
analysis	NULL
.	NULL

The	NULL
correlation	NULL
coefficient	NULL
for	NULL
the	NULL
quadratic	NULL
polynomial	NULL
used	NULL
to	NULL
fit	NULL
the	NULL
data	NULL
is	NULL
0.88	NULL
.	NULL

®	NULL
\	NULL
&	NULL
as	NULL
A	NULL
3	NULL
\	NULL
[	NULL
M	NULL
o	NULL
e	NULL
N*	NULL
a	NULL
20f3	NULL
\\	NULL
.	NULL

Z	NULL
®	NULL
&	NULL
&	NULL
®	NULL
Oa	NULL
i	NULL
TOTAL	NULL
BINDING	NULL
w	NULL
9	NULL
|3	NULL
Ne	NULL
%	NULL
9	NULL
ie	NULL
}	NULL
Z	NULL
\	NULL
»	NULL
geri	NULL
cot	NULL
<	NULL
a	NULL
C|	NULL
3	NULL
.	NULL

\	NULL
2*	NULL
``	NULL
sPECIFIC	NULL
BINDING	NULL
w	NULL
'	NULL
e	NULL
|	NULL
o	NULL
z	NULL
$	NULL
B	NULL
9	NULL
a	NULL
a	NULL
a	NULL
0	NULL
0	NULL
1	NULL
8	NULL
_o	NULL
,	NULL
2	NULL
gi	NULL
BOUND	NULL
(	NULL
M	NULL
x10	NULL
``	NULL
9	NULL
}	NULL
%	NULL
5	NULL
*A	NULL
<	NULL
£	NULL
&	NULL
o	NULL
s	NULL
}	NULL
to	NULL
E	NULL
E	NULL
a	NULL
*	NULL
5	NULL
/	NULL
o	NULL
4	NULL
A	NULL
#	NULL
a	NULL
/	NULL
a*	NULL
NONSPECIFIC	NULL
-	NULL
BINDING	NULL
a	NULL
/°/	NULL
0	NULL
_	NULL
oal	NULL
e	NULL
--	NULL
8	NULL
,	NULL
19°	NULL
19°	NULL
10°	NULL
10	NULL
[	NULL
TRiamcinoLone	NULL
AcETONIDE	NULL
]	NULL
(	NULL
M	NULL
)	NULL
Fic	NULL
.	NULL

7	NULL
.	NULL

Binding	NULL
of	NULL
triamcinolone	NULL
acetonide	NULL
in	NULL
IM-9	NULL
cytosol	NULL
as	NULL
a	NULL
function	NULL
of	NULL
steroid	NULL
concentration	NULL
.	NULL

Incubations	NULL
(	NULL
0.5	NULL
mi	NULL
)	NULL
containing	NULL
100,000	NULL
x	NULL
g	NULL
IM-9	NULL
cell	NULL
supernatant	NULL
and	NULL
various	NULL
concentrations	NULL
of	NULL
radioactive	NULL
triamcinolone	NULL
acetonide	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
vehicle	NULL
or	NULL
nonradioactive	NULL
dexamethasone	NULL
were	NULL
maintained	NULL
for	NULL
20	NULL
h	NULL
at	NULL
0°C	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
10	NULL
mM	NULL
sodium	NULL
molybdate	NULL
.	NULL

At	NULL
the	NULL
end	NULL
of	NULL
the	NULL
incubation	NULL
,	NULL
the	NULL
amount	NULL
of	NULL
bound	NULL
radioactivity	NULL
in	NULL
each	NULL
sample	NULL
was	NULL
assayed	NULL
.	NULL

The	NULL
results	NULL
are	NULL
expressed	NULL
as	NULL
femtomoles	NULL
of	NULL
steroid	NULL
bound/	NULL
mg	NULL
of	NULL
protein	NULL
versus	NULL
the	NULL
free	NULL
concentration	NULL
of	NULL
the	NULL
radioactive	NULL
steroid	NULL
.	NULL

@	NULL
,	NULL
binding	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
molybdate	NULL
;	NULL
A	NULL
,	NULL
binding	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
molybdate	NULL
;	NULL
O	NULL
,	NULL
nenspecific	NULL
binding	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
molybdate	NULL
;	NULL
A	NULL
,	NULL
nonspecific	NULL
binding	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
molybdate	NULL
;	NULL
fill	NULL
,	NULL
specific	NULL
binding	NULL
,	NULL
represented	NULL
by	NULL
the	NULL
dashed	NULL
line	NULL
.	NULL

The	NULL
inset	NULL
presents	NULL
Scatchard	NULL
plots	NULL
of	NULL
the	NULL
binding	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
vehicle	NULL
with	NULL
(	NULL
&	NULL
)	NULL
and	NULL
without	NULL
(	NULL
@	NULL
)	NULL
molybdate	NULL
.	NULL

The	NULL
straight	NULL
lines	NULL
of	NULL
the	NULL
Scatchard	NULL
plots	NULL
were	NULL
determined	NULL
by	NULL
the	NULL
method	NULL
of	NULL
least	NULL
squares	NULL
.	NULL

Glucocorticoid	NULL
Receptor	NULL
Activation	NULL
and	NULL
Inactivation	NULL
were	NULL
incubated	NULL
for	NULL
20	NULL
h	NULL
with	NULL
various	NULL
concentrations	NULL
of	NULL
radiolabeled	NULL
triamcinolone	NULL
acetonide	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
10	NULL
mm	NULL
sodium	NULL
molybdate	NULL
and	NULL
binding	NULL
was	NULL
assayed	NULL
.	NULL

The	NULL
binding	NULL
curve	NULL
for	NULL
the	NULL
molybdate-containing	NULL
cytosol	NULL
is	NULL
the	NULL
same	NULL
as	NULL
that	NULL
for	NULL
the	NULL
control	NULL
.	NULL

The	NULL
apparent	NULL
dissociation	NULL
constants	NULL
calculated	NULL
from	NULL
the	NULL
slopes	NULL
of	NULL
the	NULL
Scatchard	NULL
plots	NULL
are	NULL
3.7	NULL
nM	NULL
and	NULL
3.4	NULL
nm	NULL
for	NULL
the	NULL
control	NULL
and	NULL
molybdate-containing	NULL
samples	NULL
,	NULL
respectively	NULL
.	NULL

The	NULL
rate	NULL
at	NULL
which	NULL
glucocorticoids	NULL
achieve	NULL
binding	NULL
equilibrium	NULL
at	NULL
0°C	NULL
is	NULL
very	NULL
slow	NULL
,	NULL
with	NULL
reported	NULL
rate	NULL
constants	NULL
of	NULL
association	NULL
being	NULL
in	NULL
the	NULL
range	NULL
of	NULL
3	NULL
to	NULL
9	NULL
x	NULL
10°	NULL
~	NULL
'	NULL
min~	NULL
'	NULL
(	NULL
13	NULL
,	NULL
18	NULL
)	NULL
.	NULL

Unoccupied	NULL
glucocorticoid	NULL
receptors	NULL
are	NULL
rapidly	NULL
inactivated	NULL
at	NULL
0°C	NULL
in	NULL
cytosols	NULL
prepared	NULL
from	NULL
several	NULL
tissue	NULL
sources	NULL
and	NULL
they	NULL
are	NULL
markedly	NULL
stabilized	NULL
when	NULL
bound	NULL
by	NULL
potent	NULL
ligands	NULL
like	NULL
triamcinolone	NULL
acetonide	NULL
(	NULL
13	NULL
,	NULL
18	NULL
,	NULL
25	NULL
)	NULL
.	NULL

As	NULL
pointed	NULL
out	NULL
both	NULL
by	NULL
Bell	NULL
and	NULL
Munck	NULL
(	NULL
13	NULL
)	NULL
and	NULL
by	NULL
ourselves	NULL
(	NULL
18	NULL
,	NULL
26	NULL
)	NULL
,	NULL
the	NULL
determination	NULL
of	NULL
dissociation	NULL
constants	NULL
by	NULL
the	NULL
approach	NULL
used	NULL
in	NULL
the	NULL
experiment	NULL
of	NULL
Fig	NULL
.	NULL

7	NULL
is	NULL
complicated	NULL
by	NULL
the	NULL
fact	NULL
that	NULL
the	NULL
unoccupied	NULL
receptor	NULL
is	NULL
being	NULL
inactivated	NULL
during	NULL
the	NULL
time	NULL
that	NULL
the	NULL
slow	NULL
binding	NULL
reaction	NULL
is	NULL
taking	NULL
place	NULL
.	NULL

In	NULL
cytosol	NULL
from	NULL
rat	NULL
thymic	NULL
lymphocytes	NULL
,	NULL
for	NULL
example	NULL
,	NULL
the	NULL
rate	NULL
of	NULL
receptor	NULL
inactivation	NULL
is	NULL
fast	NULL
enough	NULL
to	NULL
significantly	NULL
alter	NULL
the	NULL
binding	NULL
curve	NULL
,	NULL
particularly	NULL
at	NULL
low	NULL
receptor	NULL
occupancy	NULL
,	NULL
and	NULL
Scatchard	NULL
plots	NULL
of	NULL
the	NULL
binding	NULL
may	NULL
not	NULL
yield	NULL
a	NULL
valid	NULL
estimation	NULL
of	NULL
the	NULL
dissociation	NULL
constant	NULL
(	NULL
13	NULL
,	NULL
18	NULL
,	NULL
26	NULL
)	NULL
.	NULL

The	NULL
experiment	NULL
of	NULL
Fig	NULL
.	NULL

8	NULL
was	NULL
carried	NULL
out	NULL
to	NULL
show	NULL
that	NULL
the	NULL
data	NULL
of	NULL
Fig	NULL
.	NULL

7	NULL
represent	NULL
a	NULL
good	NULL
approximation	NULL
of	NULL
equilibrium	NULL
binding	NULL
values	NULL
and	NULL
thus	NULL
yield	NULL
a	NULL
valid	NULL
Kp	NULL
.	NULL

Aliquots	NULL
of	NULL
cytosol	NULL
were	NULL
incubated	NULL
with	NULL
a	NULL
concentration	NULL
of	NULL
triamcinolone	NULL
acetonide	NULL
sufficient	NULL
to	NULL
occupy	NULL
about	NULL
20	NULL
%	NULL
of	NULL
the	NULL
binding	NULL
sites	NULL
.	NULL

Maximum	NULL
binding	NULL
is	NULL
achieved	NULL
at	NULL
10	NULL
to	NULL
20	NULL
h	NULL
and	NULL
it	NULL
declines	NULL
very	NULL
slowly	NULL
thereafter	NULL
.	NULL

Free	NULL
(	NULL
i.e	NULL
.	NULL

SPECIFIC	NULL
BINDING	NULL
(	NULL
fmoles/mg	NULL
proteinx102	NULL
}	NULL
)	NULL
o	NULL
_	NULL
.	NULL

0	NULL
20	NULL
40	NULL
60	NULL
80	NULL
100	NULL
INCUBATION	NULL
TIME	NULL
(	NULL
hours	NULL
)	NULL
Fic	NULL
.	NULL

8	NULL
.	NULL

Demonstration	NULL
of	NULL
steady	NULL
state	NULL
binding	NULL
at	NULL
partial	NULL
receptor	NULL
occupancy	NULL
.	NULL

Aliquots	NULL
of	NULL
a	NULL
100,000	NULL
x	NULL
g	NULL
IM-9	NULL
cell	NULL
supernatant	NULL
containing	NULL
10	NULL
mM	NULL
sodium	NULL
molybdate	NULL
(	NULL
A	NULL
)	NULL
or	NULL
vehicle	NULL
(	NULL
@	NULL
)	NULL
were	NULL
incubated	NULL
(	NULL
with	NULL
and	NULL
without	NULL
nonradioactive	NULL
competing	NULL
dexamethasone	NULL
)	NULL
at	NULL
0°C	NULL
with	NULL
a	NULL
concentration	NULL
of	NULL
[	NULL
*H	NULL
triamcinolone	NULL
acetonide	NULL
sufficient	NULL
to	NULL
occupy	NULL
approximately	NULL
20	NULL
%	NULL
of	NULL
the	NULL
specific	NULL
binding	NULL
sites	NULL
at	NULL
equilib-rium	NULL
.	NULL

At	NULL
the	NULL
indicated	NULL
times	NULL
,	NULL
the	NULL
specific	NULL
binding	NULL
of	NULL
triamcinolone	NULL
acetonide	NULL
was	NULL
determined	NULL
on	NULL
duplicate	NULL
samples	NULL
.	NULL

The	NULL
inset	NULL
shows	NULL
the	NULL
same	NULL
binding	NULL
time	NULL
course	NULL
drawn	NULL
as	NULL
a	NULL
solid	NULL
line	NULL
and	NULL
binding	NULL
values	NULL
obtained	NULL
by	NULL
incubating	NULL
the	NULL
supernatant	NULL
with	NULL
a	NULL
concentration	NULL
of	NULL
[	NULL
*H	NULL
Itriamcinolone	NULL
acetonide	NULL
(	NULL
3	NULL
X	NULL
10~°	NULL
M	NULL
)	NULL
that	NULL
is	NULL
well	NULL
beyond	NULL
that	NULL
required	NULL
to	NULL
yield	NULL
occupancy	NULL
of	NULL
all	NULL
specific	NULL
binding	NULL
sites	NULL
.	NULL

The	NULL
initial	NULL
amount	NULL
of	NULL
specific	NULL
binding	NULL
was	NULL
assayed	NULL
by	NULL
adding	NULL
the	NULL
labeled	NULL
steroid	NULL
at	NULL
zero	NULL
time	NULL
and	NULL
assaying	NULL
at	NULL
9	NULL
h.	NULL
Free	NULL
receptor	NULL
in	NULL
equilibrium	NULL
with	NULL
the	NULL
bound	NULL
steroid	NULL
was	NULL
assayed	NULL
by	NULL
adding	NULL
the	NULL
labeled	NULL
steroid	NULL
(	NULL
3	NULL
x	NULL
10~°	NULL
M	NULL
)	NULL
to	NULL
molybdate-containing	NULL
or	NULL
control	NULL
samples	NULL
that	NULL
had	NULL
been	NULL
incubated	NULL
for	NULL
72	NULL
h	NULL
with	NULL
the	NULL
low	NULL
,	NULL
subsaturating	NULL
concentration	NULL
of	NULL
labeled	NULL
ligand	NULL
and	NULL
assaying	NULL
binding	NULL
8	NULL
h	NULL
later	NULL
(	NULL
solid	NULL
lines	NULL
to	NULL
dots	NULL
)	NULL
.	NULL

The	NULL
dashed	NULL
lines	NULL
give	NULL
an	NULL
approximation	NULL
of	NULL
the	NULL
rate	NULL
of	NULL
inactivation	NULL
of	NULL
the	NULL
specific	NULL
binding	NULL
capacity	NULL
of	NULL
the	NULL
free	NULL
receptor	NULL
at	NULL
0°C	NULL
in	NULL
the	NULL
presence	NULL
and	NULL
absence	NULL
of	NULL
molybdate	NULL
.	NULL

Glucocorticoid	NULL
Receptor	NULL
Activation	NULL
and	NULL
Inactivation	NULL
unbound	NULL
)	NULL
receptor	NULL
can	NULL
be	NULL
demonstrated	NULL
even	NULL
after	NULL
72	NULL
h	NULL
at	NULL
0°C	NULL
.	NULL

The	NULL
free	NULL
receptor	NULL
is	NULL
very	NULL
stable	NULL
,	NULL
having	NULL
a	NULL
/	NULL
,	NULL
»	NULL
of	NULL
about	NULL
80	NULL
h	NULL
at	NULL
0°C	NULL
,	NULL
and	NULL
it	NULL
is	NULL
even	NULL
more	NULL
stable	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
molybdate	NULL
.	NULL

If	NULL
the	NULL
temperature	NULL
of	NULL
the	NULL
cytosol	NULL
is	NULL
raised	NULL
to	NULL
25°C	NULL
,	NULL
the	NULL
binding	NULL
capacity	NULL
is	NULL
rapidly	NULL
lost	NULL
(	NULL
Fig	NULL
.	NULL

9	NULL
)	NULL
.	NULL

The	NULL
rate	NULL
of	NULL
receptor	NULL
inactivation	NULL
is	NULL
not	NULL
affected	NULL
by	NULL
the	NULL
presence	NULL
of	NULL
dithiothreitol	NULL
but	NULL
it	NULL
is	NULL
slowed	NULL
tremendously	NULL
by	NULL
10	NULL
mm	NULL
molybdate	NULL
(	NULL
Fig	NULL
.	NULL

9	NULL
and	NULL
Table	NULL
I	NULL
)	NULL
.	NULL

Vanadate	NULL
,	NULL
another	NULL
Group	NULL
6A	NULL
transition	NULL
metal	NULL
oxide	NULL
,	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
inhibit	NULL
transformation	NULL
of	NULL
the	NULL
avian	NULL
progesterone	NULL
-receptor	NULL
complex	NULL
to	NULL
the	NULL
DNA-binding	NULL
state	NULL
(	NULL
27	NULL
)	NULL
and	NULL
,	NULL
as	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

10	NULL
,	NULL
it	NULL
inhibits	NULL
inactivation	NULL
of	NULL
unbound	NULL
glucocorticoid	NULL
receptors	NULL
.	NULL

Although	NULL
vanadate	NULL
is	NULL
somewhat	NULL
more	NULL
potent	NULL
than	NULL
molybdate	NULL
at	NULL
low	NULL
concentrations	NULL
,	NULL
its	NULL
stabilizing	NULL
effect	NULL
actually	NULL
decreases	NULL
when	NULL
it	NULL
is	NULL
present	NULL
at	NULL
1	NULL
mM	NULL
and	NULL
higher	NULL
.	NULL

The	NULL
decrease	NULL
in	NULL
efficacy	NULL
at	NULL
higher	NULL
concentrations	NULL
is	NULL
observed	NULL
in	NULL
rat	NULL
liver	NULL
as	NULL
well	NULL
as	NULL
human	NULL
lymphocyte	NULL
cytosol	NULL
and	NULL
in	NULL
both	NULL
Tris	NULL
and	NULL
Hepes	NULL
buffers	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Table	NULL
II	NULL
,	NULL
fluoride	NULL
partially	NULL
inhibits	NULL
receptor	NULL
inactivation	NULL
but	NULL
glucose	NULL
1-phosphate	NULL
,	NULL
which	NULL
inhibits	NULL
inactivation	NULL
of	NULL
both	NULL
mouse	NULL
fibroblast	NULL
and	NULL
rat	NULL
liver	NULL
receptors	NULL
(	NULL
7	NULL
)	NULL
,	NULL
is	NULL
ineffective	NULL
.	NULL

ATP	NULL
also	NULL
inhibits	NULL
the	NULL
inactivation	NULL
of	NULL
cytosol-bind-ing	NULL
capacity	NULL
.	NULL

A	NULL
maximum	NULL
of	NULL
about	NULL
50	NULL
%	NULL
inhibition	NULL
of	NULL
receptor	NULL
inactivation	NULL
is	NULL
achieved	NULL
with	NULL
3	NULL
mm	NULL
ATP	NULL
(	NULL
Fig	NULL
.	NULL

11	NULL
)	NULL
.	NULL

Although	NULL
ATP	NULL
is	NULL
the	NULL
best	NULL
inhibitor	NULL
of	NULL
the	NULL
nucleotides	NULL
(	NULL
Table	NULL
III	NULL
)	NULL
,	NULL
GTP	NULL
,	NULL
CTP	NULL
,	NULL
and	NULL
UTP	NULL
are	NULL
also	NULL
active	NULL
.	NULL

ADP	NULL
and	NULL
AMP	NULL
are	NULL
less	NULL
effective	NULL
than	NULL
ATP	NULL
in	NULL
human	NULL
lymphocyte	NULL
cytosol	NULL
but	NULL
there	NULL
is	NULL
§	NULL
O	NULL
c	NULL
a	NULL
T	NULL
``	NULL
T-	NULL
T	NULL
C	NULL
a	NULL
.	NULL

9	NULL
``	NULL
I	NULL
o	NULL
=	NULL
E	NULL
meu	NULL
_~g\/	NULL
“	NULL
004	NULL
_	NULL
a	NULL
_-	NULL
o	NULL
O	NULL
\.-_-	NULL
~	NULL
C	NULL
g	NULL
MoO3	NULL
+	NULL
DTT	NULL
y-i	NULL
U	NULL
<	NULL
4	NULL
6	NULL
.	NULL

<	NULL
4	NULL
O	NULL
(	NULL
D	NULL
<	NULL
O	NULL
<	NULL
m	NULL
Control	NULL
\	NULL
®	NULL
.	NULL

DTT	NULL
~	NULL
%	NULL
'	NULL
o	NULL
t	NULL
0	NULL
L_	NULL
__	NULL
__	NULL
sgs	NULL
--	NULL
HO	NULL
--	NULL
--	NULL
-	NULL
%	NULL
O	NULL
I	NULL
2	NULL
3	NULL
4	NULL
TIME	NULL
(	NULL
hours	NULL
)	NULL
Fic	NULL
.	NULL

9	NULL
.	NULL

Inactivation	NULL
of	NULL
unoccupied	NULL
binding	NULL
sites	NULL
in	NULL
IM-9	NULL
cytosol	NULL
at	NULL
25°C	NULL
.	NULL

A	NULL
100,000	NULL
x	NULL
g	NULL
supernatant	NULL
prepared	NULL
from	NULL
IM-9	NULL
cells	NULL
was	NULL
divided	NULL
into	NULL
several	NULL
portions	NULL
and	NULL
incubated	NULL
with	NULL
2	NULL
mM	NULL
dithiothreitol	NULL
(	NULL
@	NULL
@	NULL
,	NULL
DTT	NULL
)	NULL
,	NULL
10	NULL
mm	NULL
sodium	NULL
molybdate	NULL
(	NULL
C	NULL
,	NULL
MoO	NULL
;	NULL
)	NULL
,	NULL
molybdate	NULL
and	NULL
dithiothreitol	NULL
(	NULL
@	NULL
)	NULL
,	NULL
or	NULL
vehicle	NULL
(	NULL
0	NULL
,	NULL
control	NULL
)	NULL
.	NULL

At	NULL
the	NULL
indicated	NULL
times	NULL
,	NULL
0.4-ml	NULL
aliquots	NULL
were	NULL
removed	NULL
and	NULL
assayed	NULL
for	NULL
specific	NULL
binding	NULL
capacity	NULL
at	NULL
0°C	NULL
as	NULL
described	NULL
under	NULL
``	NULL
Methods	NULL
.	NULL
``	NULL

The	NULL
values	NULL
represent	NULL
the	NULL
average	NULL
of	NULL
duplicate	NULL
determinations	NULL
expressed	NULL
as	NULL
femtomoles	NULL
of	NULL
triamcinolone	NULL
acetonide	NULL
bound	NULL
specifically	NULL
per	NULL
mg	NULL
of	NULL
protein	NULL
versus	NULL
the	NULL
time	NULL
of	NULL
incubation	NULL
at	NULL
25°C	NULL
.	NULL

439	NULL
100F	NULL
80	NULL
60r	NULL
ao	NULL
}	NULL
20	NULL
0	NULL
0.0	NULL
O	NULL
.	NULL

LO	NULL
10	NULL
oof	NULL
``	NULL
~	NULL
-~	NULL
B	NULL
/	NULL
aof	NULL
4	NULL
t	NULL
o	NULL
60	NULL
SPECIFIC	NULL
BINDING	NULL
CAPACITY	NULL
(	NULL
%	NULL
of	NULL
zero	NULL
time	NULL
control	NULL
)	NULL
40Fr	NULL
v03	NULL
0	NULL
ZOL	NULL
/	NULL
0	NULL
,	NULL
o	NULL
9	NULL
C	NULL
0/0/	NULL
olL4	NULL
«	NULL
2	NULL
a	NULL
a	NULL
a	NULL
0	NULL
ao	NULL
!	NULL

Q.1	NULL
1.0	NULL
to	NULL
CONCENTRATION	NULL
OF	NULL
INHIBITOR	NULL
{	NULL
mM	NULL
)	NULL
Fic	NULL
.	NULL

10	NULL
.	NULL

Inhibition	NULL
of	NULL
inactivation	NULL
of	NULL
unoccupied	NULL
receptor	NULL
by	NULL
molybdate	NULL
and	NULL
vanadate	NULL
.	NULL

Aliquots	NULL
of	NULL
100,000	NULL
x	NULL
g	NULL
supernatant	NULL
prepared	NULL
from	NULL
IM-9	NULL
cells	NULL
(	NULL
A	NULL
)	NULL
or	NULL
rat	NULL
liver	NULL
(	NULL
B	NULL
)	NULL
were	NULL
incubated	NULL
for	NULL
2	NULL
h	NULL
at	NULL
25°C	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
vehicle	NULL
(	NULL
&	NULL
)	NULL
,	NULL
or	NULL
various	NULL
concentrations	NULL
of	NULL
sodium	NULL
molybdate	NULL
(	NULL
@	NULL
)	NULL
or	NULL
sodium	NULL
metavanadate	NULL
(	NULL
0	NULL
)	NULL
.	NULL

After	NULL
2	NULL
h	NULL
,	NULL
the	NULL
specific	NULL
binding	NULL
capacity	NULL
was	NULL
assayed	NULL
at	NULL
0°C	NULL
as	NULL
described	NULL
under	NULL
``	NULL
Methods	NULL
.	NULL
``	NULL

The	NULL
results	NULL
are	NULL
expressed	NULL
as	NULL
a	NULL
per	NULL
cent	NULL
of	NULL
the	NULL
binding	NULL
capacity	NULL
present	NULL
at	NULL
zero	NULL
time	NULL
.	NULL

The	NULL
supernatant	NULL
and	NULL
all	NULL
additions	NULL
were	NULL
prepared	NULL
in	NULL
10	NULL
mm	NULL
Tris	NULL
without	NULL
EDTA	NULL
in	NULL
A	NULL
and	NULL
in	NULL
10	NULL
mm	NULL
Hepes	NULL
buffer	NULL
without	NULL
EDTA	NULL
in	NULL
B.	NULL
TasLE	NULL
II	NULL
Effect	NULL
of	NULL
known	NULL
glucocorticoid	NULL
receptor	NULL
stabilizing	NULL
compounds	NULL
on	NULL
inactivation	NULL
of	NULL
the	NULL
binding	NULL
capacity	NULL
of	NULL
IM-9	NULL
cytosol	NULL
IM-9	NULL
cytosol	NULL
(	NULL
100,000	NULL
x	NULL
g	NULL
supernatant	NULL
)	NULL
was	NULL
incubated	NULL
for	NULL
2	NULL
h	NULL
at	NULL
25°C	NULL
,	NULL
with	NULL
2	NULL
mm	NULL
dithiothreitol	NULL
,	NULL
100	NULL
mM	NULL
sodium	NULL
fluoride	NULL
,	NULL
I0	NULL
mm	NULL
sodium	NULL
molybdate	NULL
,	NULL
5	NULL
mM	NULL
glucose	NULL
1-phosphate	NULL
,	NULL
or	NULL
1	NULL
mm	NULL
ATP	NULL
.	NULL

Specific	NULL
binding	NULL
capacity	NULL
was	NULL
assayed	NULL
at	NULL
time	NULL
zero	NULL
and	NULL
after	NULL
2	NULL
h.	NULL
Each	NULL
value	NULL
represents	NULL
the	NULL
average	NULL
of	NULL
duplicate	NULL
determinations	NULL
expressed	NULL
as	NULL
femtomoles	NULL
of	NULL
triamcinolone	NULL
acetonide	NULL
bound	NULL
specifically/mg	NULL
of	NULL
protein	NULL
.	NULL

Specific	NULL
binding	NULL
capac-	NULL
ity	NULL
Conditions	NULL
Time	NULL
Experi-	NULL
Experi-raent	NULL
A	NULL
ment	NULL
B	NULL
h	NULL
fmol/mg	NULL
protein	NULL
Cytosol	NULL
alone	NULL
zero	NULL
time	NULL
1070	NULL
1760	NULL
Cytosol	NULL
alone	NULL
2	NULL
149	NULL
781	NULL
Plus	NULL
dithiothreitol	NULL
2	NULL
113	NULL
639	NULL
Plus	NULL
fluoride	NULL
2	NULL
639	NULL
1073	NULL
Plus	NULL
molybdate	NULL
2	NULL
1100	NULL
1690	NULL
Plus	NULL
glucose	NULL
1-	NULL
2	NULL
113	NULL
phosphate	NULL
Plus	NULL
ATP	NULL
2	NULL
1220	NULL
no	NULL
significant	NULL
difference	NULL
between	NULL
them	NULL
and	NULL
the	NULL
triphosphate	NULL
in	NULL
rat	NULL
liver	NULL
cytosol	NULL
.	NULL

Although	NULL
the	NULL
rate	NULL
of	NULL
inactivation	NULL
of	NULL
the	NULL
binding	NULL
capacity	NULL
of	NULL
IM-9	NULL
cytosol	NULL
preparations	NULL
can	NULL
be	NULL
inhibited	NULL
by	NULL
several	NULL
compounds	NULL
that	NULL
are	NULL
also	NULL
effective	NULL
in	NULL
rat	NULL
liver	NULL
,	NULL
mouse	NULL
L-cell	NULL
,	NULL
and	NULL
rat	NULL
thymocyte	NULL
cytosols	NULL
,	NULL
we	NULL
have	NULL
not	NULL
,	NULL
as	NULL
yet	NULL
,	NULL
been	NULL
able	NULL
,	NULL
as	NULL
in	NULL
the	NULL
latter	NULL
two	NULL
preparations	NULL
,	NULL
to	NULL
reactivate	NULL
the	NULL
binding	NULL
capacity	NULL
.	NULL

We	NULL
have	NULL
tried	NULL
all	NULL
of	NULL
the	NULL
conditions	NULL
that	NULL
we	NULL
have	NULL
reported	NULL
in	NULL
the	NULL
other	NULL
systems	NULL
(	NULL
11	NULL
,	NULL
12	NULL
)	NULL
and	NULL
have	NULL
not	NULL
been	NULL
able	NULL
to	NULL
reactivate	NULL
either	NULL
receptors	NULL
in	NULL
cytosol	NULL
prepared	NULL
from	NULL
cells	NULL
that	NULL
were	NULL
inactivated	NULL
by	NULL
exposure	NULL
to	NULL
nitrogen	NULL
and	NULL
glucose-free	NULL
conditions	NULL
while	NULL
intact	NULL
,	NULL
or	NULL
receptors	NULL
in	NULL
cytosol	NULL
inactivated	NULL
by	NULL
incubation	NULL
at	NULL
25°C	NULL
as	NULL
in	NULL
the	NULL
experiment	NULL
of	NULL
Fig	NULL
.	NULL

9	NULL
.	NULL

440	NULL
15	NULL
T	NULL
T	NULL
_	NULL
B	NULL
A	NULL
>	NULL
°	NULL
0	NULL
%	NULL
*A	NULL
o	NULL
plus	NULL
MoOg	NULL
5	NULL
~	NULL
and	NULL
ATP	NULL
-	NULL
&	NULL
8/	NULL
plus	NULL
Mo03	NULL
a	NULL
%	NULL
\	NULL
%	NULL
o	NULL
<	NULL
%	NULL
4	NULL
9	NULL
&	NULL
10	NULL
IO	NULL
}	NULL
o	NULL
plus	NULL
ATP	NULL
os	NULL
|	NULL
To	NULL
--	NULL
*®	NULL
--	NULL
-s	NULL
€	NULL
9	NULL
0	NULL
o	NULL
a	NULL
g	NULL
g	NULL
/	NULL
P	NULL
'	NULL
“	NULL
ATP	NULL
only	NULL
*s	NULL
L	NULL
\o	NULL
o	NULL
3	NULL
5	NULL
0/	NULL
5	NULL
\	NULL
n	NULL
ks	NULL
E	NULL
/	NULL
W	NULL
Cantrol	NULL
o	NULL
wy	NULL
®	NULL
a.	NULL
t	NULL
0L__4.__4__a_	NULL
(	NULL
g-	NULL
!	NULL

o	NULL
___	NULL
_i	NULL
.	NULL

0	NULL
2	NULL
4	NULL
6	NULL
10	NULL
0	NULL
30	NULL
60	NULL
90	NULL
ATP	NULL
CONCENTRATION	NULL
(	NULL
mM	NULL
)	NULL
INCUBATION	NULL
TIME	NULL
(	NULL
hours	NULL
)	NULL
Fic	NULL
.	NULL

11	NULL
.	NULL

Effect	NULL
of	NULL
ATP	NULL
on	NULL
inactivation	NULL
of	NULL
the	NULL
unoccupied	NULL
IM-9	NULL
receptor	NULL
.	NULL

A	NULL
,	NULL
aliquots	NULL
of	NULL
a	NULL
100,000	NULL
x	NULL
g	NULL
supernatant	NULL
were	NULL
incubated	NULL
for	NULL
90	NULL
min	NULL
at	NULL
25°C	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
various	NULL
concentrations	NULL
of	NULL
ATP	NULL
(	NULL
@	NULL
)	NULL
or	NULL
10	NULL
mm	NULL
ATP	NULL
and	NULL
10	NULL
mm	NULL
sodium	NULL
molybdate	NULL
(	NULL
&	NULL
)	NULL
.	NULL

The	NULL
specific	NULL
binding	NULL
capacity	NULL
was	NULL
assayed	NULL
as	NULL
described	NULL
under	NULL
``	NULL
Methods	NULL
.	NULL
``	NULL

O	NULL
,	NULL
binding	NULL
in	NULL
a	NULL
zero	NULL
time	NULL
control	NULL
.	NULL

B	NULL
,	NULL
aliquots	NULL
of	NULL
IM-9	NULL
cell	NULL
cytosol	NULL
were	NULL
incubated	NULL
at	NULL
25°C	NULL
for	NULL
various	NULL
times	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
3	NULL
mm	NULL
ATP	NULL
(	NULL
@	NULL
)	NULL
,	NULL
10	NULL
mx	NULL
sodium	NULL
molybdate	NULL
(	NULL
&	NULL
)	NULL
,	NULL
or	NULL
vehicle	NULL
(	NULL
0	NULL
)	NULL
and	NULL
specific	NULL
binding	NULL
capacity	NULL
was	NULL
assayed	NULL
.	NULL

Tasue	NULL
III	NULL
Effect	NULL
of	NULL
nucleotides	NULL
and	NULL
phosphate	NULL
on	NULL
inactivation	NULL
of	NULL
cytosol-binding	NULL
capacity	NULL
Cytosol	NULL
(	NULL
100,000	NULL
x	NULL
g	NULL
supernatant	NULL
)	NULL
prepared	NULL
from	NULL
IM-9	NULL
cells	NULL
or	NULL
rat	NULL
liver	NULL
was	NULL
incubated	NULL
for	NULL
90	NULL
min	NULL
at	NULL
25°C	NULL
with	NULL
the	NULL
indicated	NULL
nucleotides	NULL
(	NULL
3	NULL
mM	NULL
)	NULL
,	NULL
the	NULL
indicated	NULL
concentrations	NULL
of	NULL
sodium	NULL
phosphate	NULL
,	NULL
or	NULL
10	NULL
mM	NULL
sodium	NULL
molybdate	NULL
.	NULL

Specific	NULL
binding	NULL
was	NULL
assayed	NULL
at	NULL
time	NULL
zero	NULL
and	NULL
after	NULL
90	NULL
min	NULL
.	NULL

Each	NULL
value	NULL
represents	NULL
the	NULL
average	NULL
of	NULL
duplicate	NULL
determinations	NULL
expressed	NULL
as	NULL
femtomoles	NULL
of	NULL
triamcinolone	NULL
acetonide	NULL
bound	NULL
specifically/mg	NULL
of	NULL
protein	NULL
.	NULL

Specific	NULL
binding	NULL
capacity	NULL
Conditions	NULL
Time	NULL
.	NULL

IM-9	NULL
cytosol	NULL
Livesroiyto-min	NULL
fmoles/mg	NULL
protein	NULL
Cytosol	NULL
alone	NULL
zero	NULL
time	NULL
1090	NULL
492	NULL
Cytosol	NULL
alone	NULL
90	NULL
140	NULL
33	NULL
Plus	NULL
ATP	NULL
90	NULL
638	NULL
330	NULL
Plus	NULL
ADP	NULL
90	NULL
281	NULL
289	NULL
Plus	NULL
AMP	NULL
90	NULL
167	NULL
316	NULL
Plus	NULL
GTP	NULL
90	NULL
354	NULL
73	NULL
Plus	NULL
CTP	NULL
90	NULL
573	NULL
170	NULL
Plus	NULL
UTP	NULL
90	NULL
499	NULL
170	NULL
Plus	NULL
P	NULL
;	NULL
3	NULL
mM	NULL
90	NULL
1565	NULL
86	NULL
6	NULL
mM	NULL
90	NULL
164	NULL
9	NULL
mM	NULL
90	NULL
174	NULL
Plus	NULL
MoOi~	NULL
90	NULL
1270	NULL
549	NULL
DISCUSSION	NULL
As	NULL
mentioned	NULL
in	NULL
the	NULL
introduction	NULL
,	NULL
except	NULL
for	NULL
the	NULL
work	NULL
of	NULL
Bell	NULL
and	NULL
Munck	NULL
(	NULL
13	NULL
)	NULL
,	NULL
the	NULL
intact	NULL
cell	NULL
studies	NULL
from	NULL
which	NULL
the	NULL
concept	NULL
of	NULL
receptor	NULL
activation-inactivation	NULL
was	NULL
derived	NULL
were	NULL
carried	NULL
out	NULL
with	NULL
cells	NULL
that	NULL
were	NULL
constantly	NULL
exposed	NULL
to	NULL
radiolabeled	NULL
ligand	NULL
.	NULL

Under	NULL
such	NULL
conditions	NULL
,	NULL
the	NULL
bound	NULL
steroid	NULL
receptor	NULL
complex	NULL
is	NULL
rapidly	NULL
transformed	NULL
and	NULL
associates	NULL
with	NULL
the	NULL
cell	NULL
nucleus	NULL
.	NULL

The	NULL
interpretation	NULL
of	NULL
binding	NULL
activity	NULL
assayed	NULL
in	NULL
cytosol	NULL
prepared	NULL
from	NULL
cells	NULL
incubated	NULL
in	NULL
this	NULL
manner	NULL
is	NULL
complicated	NULL
because	NULL
of	NULL
the	NULL
partitioning	NULL
between	NULL
particulate	NULL
and	NULL
soluble	NULL
fractions	NULL
(	NULL
3	NULL
)	NULL
.	NULL

In	NULL
the	NULL
experiments	NULL
of	NULL
Figs	NULL
.	NULL

2	NULL
to	NULL
5	NULL
,	NULL
it	NULL
is	NULL
clearly	NULL
the	NULL
binding	NULL
activity	NULL
of	NULL
the	NULL
unbound	NULL
form	NULL
of	NULL
the	NULL
receptor	NULL
that	NULL
is	NULL
being	NULL
altered	NULL
.	NULL

There	NULL
is	NULL
no	NULL
specific	NULL
binding	NULL
activity	NULL
in	NULL
low	NULL
speed	NULL
pellets	NULL
prepared	NULL
from	NULL
cells	NULL
incubated	NULL
under	NULL
energy-limiting	NULL
conditions	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
glucocor-ticoid	NULL
.	NULL

In	NULL
view	NULL
of	NULL
the	NULL
lack	NULL
of	NULL
effect	NULL
of	NULL
cycloheximide	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
,	NULL
it	NULL
seems	NULL
very	NULL
unlikely	NULL
that	NULL
the	NULL
receptor	NULL
is	NULL
being	NULL
degraded	NULL
and	NULL
then	NULL
resynthesized	NULL
when	NULL
glucose	NULL
and	NULL
oxygen	NULL
are	NULL
reintroduced	NULL
.	NULL

Glucocorticoid	NULL
Receptor	NULL
Activation	NULL
and	NULL
Inactivation	NULL
The	NULL
simplest	NULL
interpretation	NULL
of	NULL
the	NULL
data	NULL
is	NULL
that	NULL
the	NULL
receptor	NULL
is	NULL
being	NULL
inactivated	NULL
as	NULL
the	NULL
ATP	NULL
level	NULL
drops	NULL
and	NULL
reactivated	NULL
as	NULL
it	NULL
rises	NULL
again	NULL
.	NULL

We	NULL
do	NULL
not	NULL
know	NULL
the	NULL
rate	NULL
of	NULL
either	NULL
the	NULL
inactivation	NULL
or	NULL
reactivation	NULL
process	NULL
,	NULL
The	NULL
rates	NULL
of	NULL
receptor	NULL
inactivation	NULL
presented	NULL
in	NULL
Figs	NULL
.	NULL

2	NULL
and	NULL
3	NULL
may	NULL
represent	NULL
the	NULL
rates	NULL
at	NULL
which	NULL
the	NULL
ATP	NULL
levels	NULL
were	NULL
lowered	NULL
under	NULL
the	NULL
energy-limiting	NULL
conditions	NULL
.	NULL

As	NULL
the	NULL
decrease	NULL
in	NULL
ATP	NULL
may	NULL
be	NULL
rate-limiting	NULL
,	NULL
it	NULL
is	NULL
possible	NULL
that	NULL
receptor	NULL
inactivation	NULL
is	NULL
a	NULL
rapid	NULL
process	NULL
like	NULL
receptor	NULL
activation	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

This	NULL
would	NULL
only	NULL
be	NULL
seen	NULL
if	NULL
the	NULL
capacity	NULL
to	NULL
reactivate	NULL
could	NULL
be	NULL
blocked	NULL
immediately	NULL
.	NULL

The	NULL
direct	NULL
relationship	NULL
between	NULL
specific	NULL
binding	NULL
capacity	NULL
and	NULL
ATP	NULL
levels	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

6	NULL
is	NULL
consistent	NULL
with	NULL
the	NULL
proposal	NULL
of	NULL
Munck	NULL
et	NULL
al	NULL
.	NULL

(	NULL
2	NULL
)	NULL
that	NULL
ATP	NULL
is	NULL
required	NULL
to	NULL
maintain	NULL
the	NULL
receptor	NULL
in	NULL
a	NULL
state	NULL
that	NULL
can	NULL
bind	NULL
steroids	NULL
.	NULL

Although	NULL
receptor	NULL
and	NULL
ATP	NULL
may	NULL
vary	NULL
coincidently	NULL
,	NULL
the	NULL
simplest	NULL
interpretation	NULL
is	NULL
that	NULL
ATP	NULL
is	NULL
in	NULL
some	NULL
way	NULL
involved	NULL
in	NULL
receptor	NULL
activation	NULL
.	NULL

The	NULL
only	NULL
way	NULL
to	NULL
directly	NULL
prove	NULL
this	NULL
would	NULL
be	NULL
to	NULL
prepare	NULL
cytosol	NULL
from	NULL
cells	NULL
exposed	NULL
to	NULL
energy-limiting	NULL
conditions	NULL
and	NULL
reactivate	NULL
the	NULL
receptor	NULL
in	NULL
an	NULL
ATP-dependent	NULL
manner	NULL
in	NULL
the	NULL
cell-free	NULL
preparation	NULL
.	NULL

We	NULL
have	NULL
not	NULL
yet	NULL
been	NULL
able	NULL
to	NULL
do	NULL
this	NULL
.	NULL

As	NULL
we	NULL
have	NULL
not	NULL
activated	NULL
receptor	NULL
in	NULL
IM-9	NULL
cytosol	NULL
,	NULL
we	NULL
have	NULL
focused	NULL
our	NULL
attention	NULL
here	NULL
on	NULL
the	NULL
inactivation	NULL
.	NULL

Although	NULL
the	NULL
unbound	NULL
IM-9	NULL
receptor	NULL
is	NULL
very	NULL
stable	NULL
at	NULL
0°C	NULL
(	NULL
Fig	NULL
.	NULL

8	NULL
)	NULL
,	NULL
it	NULL
is	NULL
rapidly	NULL
inactivated	NULL
at	NULL
higher	NULL
temperatures	NULL
.	NULL

The	NULL
glucocorticoid-binding	NULL
activity	NULL
of	NULL
rat	NULL
lung	NULL
(	NULL
28	NULL
)	NULL
and	NULL
thymic	NULL
lymphocyte	NULL
(	NULL
5	NULL
,	NULL
12	NULL
)	NULL
cytosol	NULL
is	NULL
also	NULL
rapidly	NULL
inactivated	NULL
and	NULL
the	NULL
receptor	NULL
in	NULL
these	NULL
preparations	NULL
is	NULL
significantly	NULL
stabilized	NULL
by	NULL
dithiothreitol	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
IM-9	NULL
cytosol	NULL
is	NULL
unaffected	NULL
by	NULL
addition	NULL
of	NULL
reducing	NULL
equivalents	NULL
(	NULL
Fig	NULL
.	NULL

9	NULL
)	NULL
.	NULL

Molybdate	NULL
stabilizes	NULL
the	NULL
binding	NULL
activity	NULL
of	NULL
IM-9	NULL
cytosol	NULL
(	NULL
Figs	NULL
.	NULL

9	NULL
to	NULL
11	NULL
)	NULL
but	NULL
it	NULL
does	NULL
not	NULL
affect	NULL
the	NULL
amount	NULL
of	NULL
steroid	NULL
bound	NULL
at	NULL
steady	NULL
state	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
)	NULL
.	NULL

Two	NULL
other	NULL
transition	NULL
metal	NULL
oxyanions	NULL
,	NULL
vanadate	NULL
(	NULL
Fig	NULL
.	NULL

10	NULL
)	NULL
and	NULL
tungstate	NULL
,	NULL
also	NULL
stabilize	NULL
the	NULL
unbound	NULL
glucocorticoid	NULL
receptor	NULL
.	NULL

Nishigori	NULL
and	NULL
Toft	NULL
(	NULL
27	NULL
)	NULL
have	NULL
shown	NULL
that	NULL
vanadate	NULL
and	NULL
tungstate	NULL
inhibit	NULL
transformation	NULL
of	NULL
the	NULL
progesterone-receptor	NULL
complex	NULL
.	NULL

We	NULL
have	NULL
previously	NULL
reported	NULL
that	NULL
tungstate	NULL
is	NULL
a	NULL
rather	NULL
poor	NULL
inhibitor	NULL
of	NULL
receptor	NULL
inactivation	NULL
in	NULL
rat	NULL
liver	NULL
cytosol	NULL
(	NULL
29	NULL
)	NULL
,	NULL
however	NULL
,	NULL
we	NULL
have	NULL
repeated	NULL
the	NULL
experiment	NULL
in	NULL
cytosol	NULL
prepared	NULL
with	NULL
Hepes	NULL
rather	NULL
than	NULL
Tris	NULL
buffer	NULL
and	NULL
find	NULL
tungstate	NULL
to	NULL
be	NULL
almost	NULL
as	NULL
potent	NULL
as	NULL
molybdate	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Nishigori	NULL
and	NULL
Toft	NULL
(	NULL
27	NULL
)	NULL
have	NULL
shown	NULL
that	NULL
molybdate	NULL
inhibition	NULL
of	NULL
avian	NULL
progesterone	NULL
receptor	NULL
transformation	NULL
is	NULL
highly	NULL
pH-dependent	NULL
(	NULL
haif-maximal	NULL
inhibition	NULL
is	NULL
achieved	NULL
with	NULL
1	NULL
mM	NULL
molybdate	NULL
at	NULL
pH	NULL
8.0	NULL
and	NULL
0.1	NULL
mM	NULL
at	NULL
ph	NULL
7.0	NULL
)	NULL
,	NULL
and	NULL
the	NULL
very	NULL
weak	NULL
stabilization	NULL
of	NULL
unbound	NULL
glucocorticoid	NULL
receptor	NULL
that	NULL
we	NULL
originally	NULL
observed	NULL
with	NULL
tungstate	NULL
may	NULL
reflect	NULL
a	NULL
problem	NULL
with	NULL
pH	NULL
.	NULL

Given	NULL
the	NULL
decreasing	NULL
effect	NULL
of	NULL
vanadate	NULL
at	NULL
high	NULL
concentrations	NULL
(	NULL
Fig	NULL
.	NULL

10	NULL
)	NULL
,	NULL
molybdate	NULL
would	NULL
seem	NULL
to	NULL
be	NULL
the	NULL
best	NULL
transition	NULL
metal	NULL
oxyanion	NULL
for	NULL
preventing	NULL
inactivation	NULL
of	NULL
unoccupied	NULL
receptors	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Munck	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Brinck-Johnsen	NULL
,	NULL
T.	NULL
(	NULL
1968	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

243	NULL
,	NULL
5556-5565	NULL
2	NULL
,	NULL
Munck	NULL
,	NULL
A.	NULL
,	NULL
Wira	NULL
,	NULL
C.	NULL
,	NULL
Young	NULL
,	NULL
D.	NULL
A.	NULL
,	NULL
Mosher	NULL
,	NULL
K.	NULL
M.	NULL
,	NULL
Hallahan	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
Bell	NULL
,	NULL
P.	NULL
A	NULL
.	NULL

(	NULL
1972	NULL
)	NULL
J.	NULL
Steroid	NULL
Biochem	NULL
.	NULL

3	NULL
,	NULL
567-578	NULL
3	NULL
.	NULL

Ishii	NULL
,	NULL
D.	NULL
N.	NULL
,	NULL
Pratt	NULL
,	NULL
W.	NULL
B.	NULL
,	NULL
and	NULL
Aronow	NULL
,	NULL
L.	NULL
(	NULL
1972	NULL
)	NULL
Biochemistry	NULL
11	NULL
,	NULL
3896-3904	NULL
4	NULL
.	NULL

Chader	NULL
,	NULL
G.	NULL
J	NULL
.	NULL

(	NULL
1973	NULL
)	NULL
J.	NULL
Neurochem	NULL
.	NULL

21	NULL
,	NULL
1525-1532	NULL
5	NULL
.	NULL

Rees	NULL
,	NULL
A.	NULL
M.	NULL
,	NULL
and	NULL
Bell	NULL
,	NULL
P.	NULL
A	NULL
.	NULL

(	NULL
1975	NULL
)	NULL
Biochim	NULL
.	NULL

Biophys	NULL
.	NULL

Acta	NULL
411	NULL
,	NULL
121-132	NULL
6	NULL
.	NULL

Sloman	NULL
,	NULL
J.	NULL
C.	NULL
,	NULL
and	NULL
Bell	NULL
,	NULL
P.	NULL
A	NULL
.	NULL

(	NULL
1976	NULL
)	NULL
Biochim	NULL
.	NULL

Biophys	NULL
.	NULL

Acta	NULL
428	NULL
,	NULL
403-413	NULL
7	NULL
.	NULL

Nielsen	NULL
,	NULL
C.	NULL
J.	NULL
,	NULL
Sando	NULL
,	NULL
J.	NULL
J.	NULL
,	NULL
Vogel	NULL
,	NULL
W.	NULL
M.	NULL
,	NULL
and	NULL
Pratt	NULL
,	NULL
W.	NULL
B	NULL
.	NULL

(	NULL
1977	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

252	NULL
,	NULL
7568-7578	NULL
8	NULL
.	NULL

Nielsen	NULL
,	NULL
C.	NULL
J.	NULL
,	NULL
Vogel	NULL
,	NULL
W.	NULL
M.	NULL
,	NULL
and	NULL
Pratt	NULL
,	NULL
W.	NULL
B	NULL
.	NULL

(	NULL
1977	NULL
)	NULL
Cancer	NULL
Res	NULL
.	NULL

37	NULL
,	NULL
3420-3426	NULL
9	NULL
.	NULL

Nielsen	NULL
,	NULL
C.	NULL
J.	NULL
,	NULL
Sando	NULL
,	NULL
J.	NULL
J.	NULL
,	NULL
and	NULL
Pratt	NULL
,	NULL
W.	NULL
B	NULL
.	NULL

(	NULL
1977	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

74	NULL
,	NULL
1398-1402	NULL
10	NULL
.	NULL

Sando	NULL
,	NULL
J.	NULL
J.	NULL
,	NULL
Nielsen	NULL
,	NULL
C.	NULL
J.	NULL
,	NULL
and	NULL
Pratt	NULL
,	NULL
W.	NULL
B	NULL
.	NULL

(	NULL
1977	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

Glucocorticoid	NULL
Receptor	NULL
Activation	NULL
and	NULL
Inactivation	NULL
252	NULL
,	NULL
7579-7582	NULL
Sando	NULL
,	NULL
J.	NULL
J.	NULL
,	NULL
La	NULL
Forest	NULL
,	NULL
A.	NULL
C.	NULL
,	NULL
and	NULL
Pratt	NULL
,	NULL
W.	NULL
B	NULL
.	NULL

(	NULL
1979	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

254	NULL
,	NULL
4772-4778	NULL
Sando	NULL
,	NULL
J.	NULL
J.	NULL
,	NULL
Hammond	NULL
,	NULL
N.	NULL
D.	NULL
,	NULL
Stratford	NULL
,	NULL
C.	NULL
A.	NULL
,	NULL
and	NULL
Pratt	NULL
,	NULL
W.	NULL
B	NULL
.	NULL

(	NULL
1979	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

254	NULL
,	NULL
4779-4789	NULL
Bell	NULL
,	NULL
P.	NULL
A.	NULL
,	NULL
and	NULL
Munck	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1973	NULL
)	NULL
Biochem	NULL
.	NULL

J	NULL
.	NULL

136	NULL
,	NULL
97-102	NULL
DeMeyts	NULL
,	NULL
P.	NULL
(	NULL
1976	NULL
)	NULL
in	NULL
Methods	NULL
in	NULL
Receptor	NULL
Research	NULL
(	NULL
Blecher	NULL
,	NULL
M.	NULL
,	NULL
ed	NULL
)	NULL
pp	NULL
.	NULL

301-383	NULL
,	NULL
Marcel	NULL
Dekker	NULL
,	NULL
New	NULL
York	NULL
Neel	NULL
,	NULL
J.	NULL
V.	NULL
,	NULL
Mohrenweiser	NULL
,	NULL
H.	NULL
W.	NULL
,	NULL
and	NULL
Meisler	NULL
,	NULL
M.	NULL
H.	NULL
(	NULL
1980	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sei	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

77	NULL
,	NULL
6037-6041	NULL
Phillips	NULL
,	NULL
H.	NULL
J.	NULL
,	NULL
and	NULL
Terryberry	NULL
,	NULL
J.	NULL
E.	NULL
(	NULL
1957	NULL
)	NULL
Exp	NULL
.	NULL

Cell	NULL
Res	NULL
.	NULL

13	NULL
,	NULL
341-347	NULL
Schulte	NULL
,	NULL
H.	NULL
F.	NULL
,	NULL
Nielsen	NULL
,	NULL
C.	NULL
J.	NULL
,	NULL
Sando	NULL
,	NULL
J.	NULL
J.	NULL
,	NULL
and	NULL
Pratt	NULL
,	NULL
W.	NULL
B	NULL
.	NULL

(	NULL
1976	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

251	NULL
,	NULL
2279-2289	NULL
Pratt	NULL
,	NULL
W.	NULL
B.	NULL
,	NULL
Kaine	NULL
,	NULL
J.	NULL
L.	NULL
,	NULL
and	NULL
Pratt	NULL
,	NULL
D.	NULL
V.	NULL
(	NULL
1975	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

250	NULL
,	NULL
4584-4591	NULL
Oyama	NULL
,	NULL
V.	NULL
,	NULL
and	NULL
Eagle	NULL
,	NULL
H.	NULL
(	NULL
1956	NULL
)	NULL
Proc	NULL
.	NULL

Soc	NULL
.	NULL

Exp	NULL
.	NULL

Biol	NULL
.	NULL

Med	NULL
.	NULL

91	NULL
,	NULL
305-307	NULL
20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

441	NULL
Pratt	NULL
,	NULL
W.	NULL
B.	NULL
,	NULL
and	NULL
Aronow	NULL
,	NULL
L.	NULL
(	NULL
1966	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

241	NULL
,	NULL
5244-5250	NULL
Lowry	NULL
,	NULL
O.	NULL
H.	NULL
,	NULL
Roberts	NULL
,	NULL
N.	NULL
R.	NULL
,	NULL
and	NULL
Kapphan	NULL
,	NULL
J.	NULL
I	NULL
.	NULL

(	NULL
1957	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

224	NULL
,	NULL
1047-1064	NULL
Marks	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
and	NULL
Medzihradsky	NULL
,	NULL
F.	NULL
(	NULL
1974	NULL
)	NULL
Mol	NULL
.	NULL

Pharmacol	NULL
.	NULL

10	NULL
,	NULL
837-848	NULL
Norman	NULL
,	NULL
M.	NULL
R.	NULL
,	NULL
and	NULL
Thompson	NULL
,	NULL
E.	NULL
B	NULL
.	NULL

(	NULL
1977	NULL
)	NULL
Cancer	NULL
Res	NULL
.	NULL

37	NULL
,	NULL
3785-3791	NULL
Hackney	NULL
,	NULL
J.	NULL
F.	NULL
,	NULL
and	NULL
Pratt	NULL
,	NULL
W.	NULL
B	NULL
.	NULL

(	NULL
1971	NULL
)	NULL
Biochemistry	NULL
10	NULL
,	NULL
3002-3008	NULL
Pratt	NULL
,	NULL
W.	NULL
B.	NULL
,	NULL
and	NULL
Ishii	NULL
,	NULL
D.	NULL
N.	NULL
(	NULL
1972	NULL
)	NULL
Biochemistry	NULL
11	NULL
,	NULL
1401-1410	NULL
Kaine	NULL
,	NULL
J.	NULL
L.	NULL
,	NULL
Nielsen	NULL
,	NULL
C.	NULL
J.	NULL
,	NULL
and	NULL
Pratt	NULL
,	NULL
W.	NULL
B	NULL
.	NULL

(	NULL
1975	NULL
)	NULL
Mol	NULL
.	NULL

Pharmacol	NULL
.	NULL

11	NULL
,	NULL
578-587	NULL
Nishigori	NULL
,	NULL
H.	NULL
,	NULL
and	NULL
Toft	NULL
,	NULL
D.	NULL
(	NULL
1980	NULL
)	NULL
Biochemistry	NULL
19	NULL
,	NULL
77-83	NULL
Granberg	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
and	NULL
Ballard	NULL
,	NULL
P.	NULL
L.	NULL
(	NULL
1977	NULL
)	NULL
Endocrinology	NULL
100	NULL
,	NULL
1160-1168	NULL
Leach	NULL
,	NULL
K.	NULL
L.	NULL
,	NULL
Dahmer	NULL
,	NULL
M.	NULL
K.	NULL
,	NULL
Hammond	NULL
,	NULL
N.	NULL
D.	NULL
,	NULL
Sando	NULL
,	NULL
J.	NULL
J.	NULL
,	NULL
and	NULL
Pratt	NULL
,	NULL
W.	NULL
B	NULL
.	NULL

(	NULL
1979	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

254	NULL
,	NULL
11884-11890	NULL

